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Determination	of	Molecular	Profiles	of	BRCA1 and  
BRCA2 Breast Cancers
G. Banneau,* M. Guedj,† R. Schiappa,† F. Petel,† N. Sévenet,* I. 
De Mascarel,* G. Mac Grogan,* M. Longy,* F. Bonnet.* *Institut 
Bergonié, INSERM, Unit-M – U916 VINCO, Bordeaux, and †Ligue 
Nationale Contre le Cancer, CIT – Recherche, Paris, France.
Background: Germline mutation screening of BRCA1 and BRCA2 genes 
is performed in suspected familial breast cancer cases, but a causative mutation 
is found in only 30% of patients. The development of additional methods to 
identify good candidates for BRCA1 and BRCA2 analysis would therefore increase 
the efficacy of diagnostic mutation screening. With this in mind, we developed 
a study to determine molecular signatures of BRCA1—or BRCA2—mutated 
breast cancers.
Materials and Methods: array-c g h  (comparative genomic hybridization) 
and transcriptomic analysis were performed on a series of 103 familial breast 
cancers. The series included 7 breast cancers with a BRCA1 mutation and 5 breast 
cancers with a BRCA2 mutation. The remaining 91 cases were obtained from 
73 families selected on the basis of at least 3 affected first-degree relatives or 
at least 2 affected first-degree relatives with breast cancer at an average age of 
45 years. array-c g h  analyses were performed on a 4407 BAC-array (CIT-V8) 
manufactured by IntegraGen. Transcriptomic analyses were performed using an 
affymetrix Human Genome U133 Plus 2.0 chip.
Results: Using supervised clustering analyses we identified two 
transcriptomic signatures: one for BRCA1-mutated breast cancers consisting of 
600 probe sets and another for BRCA2-mutated breast cancers also consisting 
of 600 probes sets. We also defined c g h -array signatures, based on the presence 
of specific genomic rearrangements, one for BRCA1-mutated breast cancers and 
one for BRCA2-mutated breast cancers.
Conclusions: This study identified molecular signatures of breast cancers 
with BRCA1 or BRCA2 germline mutations. Genes present in these signatures 
could be exploited to find new markers for such breast cancers. We also identified 
specific genomic rearrangements in these breast cancers, which could be screened 
for in a diagnostic setting using fluorescence in situ hybridization, thus improving 
patient selection for BRCA1 and BRCA2 molecular genetic analysis.
Identification	and	Characterization	of	Splice	Variants	in	BRCA 
Genes Using Reverse Transcriptase Polymerase Chain Reaction 
and	Multiplex	Ligation-Dependent	Probe	Amplification
R.D. Brandão,*† K. van Roozendaal,* D. Tserpelis,* E. Goméz 
García,*† M.J. Blok.* *Department of Clinical Genetics, University 
Hospital Maastricht, and †GROW – School for Oncology and Develop-
mental Biology, Maastricht University, Maastricht, Limb, Netherlands.
Objectives: A large subset of the unclassified variants in the BRCA1/2 
genes are in intronic sequences or close to exon–intron boundaries and may 
affect splicing. Putative BRCA1 and BRCA2 splice variants, as predicted in 
silico, were studied experimentally using reverse transcriptase polymerase chain 
reaction (r t -p c r ) and a new approach based on multiplex ligation-dependent 
probe amplification (m l p a ) technology.
Methods: Short-term lymphocyte cultures from controls and unclassified 
sequence variant carriers were established with p h a  and il-2. analysis by r t -p c r  
was performed for the following BRCA2 putative splice variants: c.425G>T, 
c.6935A>T, c.6842–3T>C, c.6943A>G, c.7976+3del2, c.8350C>T, c.8662C>T, 
c.8754+3G>C. The use of m l p a  technology was subsequently evaluated for the 
detection of aberrant splice events on well-characterized splice variants, including 
BRCA1 exon 13 and exon 22 deletions. Commercially available m l p a  kits for 
BRCA1 and BRCA2 genes were used (probes in exons), in addition to homemade 
m l p a  probe sets (probes crossing exon–exon boundaries).
Results: BRCA2 variants c.425G>T and c.7976+3del2 give rise to 
transcripts with deletions of exon 4 and exon 17 respectively, and c.8754+3G>C 
leads to 46 bp of intron retention. These variants were considered to be pathogenic. 
additionally, alternative splicing events were observed in controls, such as 
c.6842_6937del (exon 12 skipping) and c.476_631del (exon 6 and 7 skipping). 
Because these in-frame transcripts are also expressed in healthy controls and 
have an unknown function, their clinical relevance remains unclear. This has 
consequences for the classification of c.6935A>T, which leads to increased 
expression of c.6842_6937del compared with controls. We found that, with m l p a , 
it is also possible to detect alternative splicing events.
Conclusions: We characterized several new pathogenic BRCA2 splice 
variants and demonstrated that, with m l p a  technology, it is possible to set up a 
multiplex screen for semi-quantitative detection of alternative splice events that 
is also widely applicable for genes other than BRCA1/2.
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Implementation of high Throughput Parallel Sequencing in a 
Diagnostic Setting: Multiplexed Amplicon Sequencing of the 
Breast Cancer Genes BRCA1 and 2
K. De Leeneer,* J. Hellemans,* J. De Schrijver,† W. Van Criekinge,† 
A. De Paepe,* P. Coucke,* K. Claes.* *Center for Medical Genetics, 
Ghent University Hospital, and †Laboratory for Bioinformatics and 
Computational Genomics, Ghent University, Ghent, Belgium.
“Next generation” sequencing opens new perspectives for mutation analysis 
of large genes. We optimized a multi-sample barcode amplicon sequencing 
strategy for mutation detection in BRCA1 and 2 on the g s -f l x instrument 
(Roche/454 Life Sciences).
For the first two runs (POP1 and 2), 112 amplicons covering the complete 
coding sequence of BRCA1 and 2 were pooled in equimolar amounts. Per run, 
11 patients were sequenced in both directions for all amplicons. For a third run 
(POP3), all 112 amplicons were generated in 15 multiplex polymerase chain 
reaction (p c r ) reactions. Hereby, all p c r  reactions were optimized to obtain a 
final equimolar mix for all fragments (CV < 30%).
The sequence coverage was much more uniform in POP3 than in POP1 and 
POP2, indicating a successful optimization and showing that the bias introduced 
by the emulsion p c r  is limited. In POP3, less than 40× coverage was obtained 
only for 6 amplicons. all sequence reads for the 22 patients of POP1 and POP2 
were analyzed with our in-house variant identification pipeline (Deschrijver et 
al., submitted) using the empirically determined filters (minimum coverage: 40×; 
maximum homopolymer length: 7; minimum variant frequency: 33%). These 
results were compared with data obtained by Sanger sequencing, producing 0 
false negatives and 5 false positives. The filter settings applied for POP1 and 
POP2 are currently validated for POP3.
This approach is not yet cost-competitive with the high-resolution 
melting curve analysis (De Leeneer et al., 2008, 2009) currently applied in our 
laboratory, but it outperforms traditional Sanger sequencing. Further optimization 
of sequence coverage uniformity, pooling of patients, and Titanium throughput 
will allow further cost reduction. For the optimization of next-generation 
amplicon sequencing, a strong collaboration is required between people 
involved in molecular diagnostics and bio-informaticians to obtain clinically 
reliable results.
Prevalence of BRCA1/2 Mutations in Unselected and  
Selected French Canadian Breast Cancer Cases  
Diagnosed at the CRChUM
P. Ghadirian,* A. Robidoux,* J.F. Boileau,* F.S. Côté,* G. Martin,* 
C. Maugard,* E. Nassif,* E. Patocskai,* C. Potvin,* R. Younan,* W.D. 
Foulkes,† S.A. Narod‡ *Centre hospitalier de l’Université de Montréal 
(C r C h u m ) and †McGill University, Montreal, Quebec, and ‡University 
of Toronto, Toronto, Ontario, Canada.
Objectives: The main purpose of this study was to estimate the prevalence 
of BRCA gene mutations and the yield of genetic testing among unselected 
breast cancer patients less than 50 years of age compared with selected patients 
between 51 and 65 years of age (with a family history of 2 or more breast or 
ovarian cancers).
Methods: In an open-cohort clinic at the c r h u m  in which French-Canadian 
breast cancer patients from 2005–2009 were recruited, we studied 932 subjects 
(687 < 50 years of age and 245 > 50 years of age). All subjects were tested for 
BRCA gene mutations.
Results: Of the unselected women with breast cancer (<50 years of age), 
5.0% were BRCA mutation carriers (1.2% BRCA1, 3.8% BRCA2). In those with 
a family history (selected subjects or >50 years of age), 4.9% displayed BRCA 
mutations (0.8% BRCA1, 4.1% BRCA2). Among unselected patients, the refusal 
rates for the genetic tests were 10.2% and 14.9% among selected breast cancer 
patients. Of the study subjects, 99% agreed to be told the results of their genetic 
tests; the remaining 1% refused to be told their results.
Conclusions: The results of this open-cohort study of the genetic 
epidemiology of breast cancer showed that the prevalence of BRCA mutations 
among French-Canadian breast cancer patients is around 5.0% (5.0% in unselected 
or <50-year-old patients, 4.9% in selected or older subjects). This type of study 
is feasible for genetic screening and the refusal rate for participation in a genetic 
study of breast cancer is very low.
The Establishment of a Cohort of Girls in  
Ontario Breast Cancer Families
D. Hanna,* G. Glendon,* E. Maloney,† J. Knight,‡ L. Lilge,†  
D. Koller,§ I. Andrulis.‡ *Cancer Care Ontario, †University Health 
Network, ‡Mount Sinai Hospital, and §The Hospital for Sick Children 
Toronto, Ontario, Canada.
Background: Emerging evidence indicates that childhood and adolescence 
may be periods sensitive to factors associated with breast cancer initiation or 
protective against breast cancer development. To investigate factors related to 
breast cancer risk, we are planning a study of girls. The l e g a c y  (Lessons in 
Epidemiology and Genetics of Adult Cancer from Youth) study plans to examine 
several intermediate phenotypes associated with breast cancer, including pubertal 
breast development, breast tissue characteristics, age at menarche, sex and growth 
hormone levels, and their relationship with potentially modifiable early-life 
exposures, as well as genetic determinants.
Objectives: To determine the interest of parents and daughters for 
participating in l e g a c y  and to aid in its design, we are conducting a pilot study 
to evaluate the feasibility of recruitment, biospecimen, and data collection in 100 
girls; to determine whether, as compared with Tanner stage, optical spectroscopy 
can be used as an efficient measure of breast development in the girls; and to 
define parental and offspring levels of acceptance or dissatisfaction across data-
collection measures.
Methods: Parents and their 6- to 17-year-old daughters from two high-
risk cancer genetics clinics in the Greater Toronto area and those already 
enrolled in the Ontario Familial Breast Cancer registry, a U.S. National Cancer 
Institute–supported population-based registry, will be invited to participate. The 
pilot involves the completion of self- and interview-administered epidemiologic 
questionnaires for daughter and parent; clinic-administered measures of height 
and weight; blood, buccal, and urine sampling; measures of pubertal breast 
development using self–Tanner staging and experimental optical spectroscopy 
modalities; and qualitative exit interviews for thorough exploration of participant 
likes and dislikes.
Results: We will present recruitment outcomes from our first group of girls.
Conclusions: Completion of the pilot study will allow us to demonstrate 
feasibility, to estimate response rates, and to assess the interest of families in 
participating in l e g a c y .
BRCA1 and BRCA2 Mutations in Belgian Families with Breast 
and/or Ovarian Cancers
P. Hilbert, A. Destrée, F. Cavallin, C. Verellen–Dumoulin.  
Human Genetics Center, Institut de Pathologie et Génétique,  
Charleroi, Belgium.
Germline mutations in BRCA1 and BRCA2 genes cause predisposition 
to breast and ovarian cancers. Here, we describe the experience of our Human 
Genetics Center on a total of approximately 700 patients living in the southern part 
of Belgium. These patients, apparently from independent families, were referred 
by oncologists or by geneticists. all of them had a personal and/or familial history 
suggestive of genetic predisposition to breast and/or ovarian cancer.
The entire coding regions of the BRCA1 and 2 genes were screened by 
standard scanning methods (denaturing gradient gel electrophoresis, denaturing 
high-pressure liquid chromatography, or high resolution melt), followed by 
sequencing of abnormal profiles. Large rearrangements of the two genes were 
investigated by m l p a  (multiple ligation-dependent probe amplification from 
MRC-Holland).
A total of 186 variants (excluding known polymorphisms) were identified 
(106 in BRCA1, 80 in BRCA2). This represents a detection rate of 26.5%.
In BRCA1, 26 (24.5%) were variants of uncertain significance, and 80 
(75.5%) were clear mutations, of which 13 were large rearrangements of the 
gene. Four recurrent mutations (deletion from exons 8 to 13, c.2722G>T, 
c.4391_4393delinsTT, and c.5137del) account for 27.5% (respectively 
7.5%, 7.5%, 6.25%, and 6.25%) of the mutations. In BRCA2, 37 (46%) were 
variants of uncertain significance, and 43 (54%) were clear mutations, of 
which only 1 was a large rearrangement of the gene. Two recurrent mutations 
(c.9117G>A and c.4936_4939del) account for 30% (respectively 16.3% and 
14%) of the mutations.
A causal mutation has hence been identified in a total of 17.5% of the 
patients (11.4% in BRCA1, 6.1% in BRCA2). These results underline the role 
of large rearrangements of BRCA1 (16.25% of the mutations identified in this 
gene) in Belgium and point to the need for collaborative efforts to classify 
precisely variants of uncertain significance, because they represent 33.8% of 
all variants detected.
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THIrd INTErNaTIONal SYMPOSIUM ON HBOC
Breast and Ovarian Cancer Risk Among heterozygotes  
for Xeroderma Pigmentosum Nucleotide Excision  
Repair Gene Mutations
R. Moslehi. State University of New York at Albany, New York, and 
National Institutes of Health, Bethesda, Maryland, U.S.A.
Background: Xeroderma pigmentosum (x p ) is a rare autosomal recessive 
disorder with an estimated frequency of 10–6 in North america. The condition is 
characterized by severe photosensitivity, abnormal pigmentation, and an increase, 
by a factor of 1000 or more, in the risk of cancers in sun-exposed tissues (skin and 
eye) in affected individuals. The disorder is caused by mutations in a number of 
genes, all (XPA–XPG) but one (XP-variant) involved in the nucleotide excision 
repair (n e r ) pathway. The heterozygote (clinically normal-appearing carrier) 
frequency of XP gene mutations is estimated at about 1 in 300. Cancer risk of 
heterozygotes is not known. We report on the frequency of hereditary breast 
cancer among x p  families.
Methods: The study population consists of 22 x p  families with detailed 
multi-generation pedigrees and epidemiology information ascertained under a 
protocol to study the natural history of the disorder. Hereditary breast cancer 
was defined as the occurrence of at least 2 cases of premenopausal breast cancer 
(diagnosed <50 years of age) or 1 case of premenopausal breast cancer and 1 
case of ovarian cancer in one side of the family.
Results: The family histories of 5 of the 22 x p  patients were compatible 
with hereditary breast cancer. In x p  family r1, with causative mutations in 
XPA, there were 4 cases (including the heterozygote mother of the proband) of 
premenopausal breast cancer, 1 case of ovarian cancer, and 1 case of prostate 
cancer in the maternal side. Comprehensive sequencing failed to identify a 
mutation in the BRCA1 and BRCA2 genes in this family. Overall, a family history 
compatible with hereditary breast cancer was found in approximately 23% of 
x p  families reported here.
Conclusions: Heterozygote carriers of XP gene mutations may be at 
increased risk for breast and ovarian cancer. a proportion of breast and ovarian 
cancer cases in the population may be attributed to mutations and polymorphisms 
in the n e r  genes.
Improvement in the Detection Rate of the BRCA1/BRCA2 French-Ca-
nadian Mutation Panel at the Service de Médecine Génique, ChUM
S. Nolet, K. Latour, S. Côté, N. Dumas, M.C. Binet, M. Breguet, L. Ga-
boury, P. Hamet, N. Larouche, G. Proulx, D. Provencher, J. Richard, C. 
Wilmart, C. Maugard. Centre hospitalier de l’Université de Montréal 
(C h u m ), Montreal, Quebec, Canada.
Introduction: The genetics of the French-Canadian (f c) population of 
Quebec is shaped by well-documented founder effects that have allowed for the 
identification of common mutations in specific genes. In BRCA1 and BRCA2 
hereditary breast and ovarian cancer, several mutations are part of a f c panel 
which is used as a first line of testing.
Objectives: To evaluate the detection rate of the f c panel currently used in 
the c h u m  diagnostic laboratory. To determine the change in detection rate when 
mutations, reported in at least two distinct f c families, are added to the panel.
Methods: a retrospective review of results obtained for f c families tested 
through the Hereditary Cancer Clinic using the laboratory and clinical records. 
Included in our analysis were index cases for whom the affected branch of the family 
was of f c descent, for whom a whole blood sample could be obtained, and who had 
both panel testing and sequencing if panel testing was negative (n = 301).
Results: From January 2005 to december 2008, 408 cases of f c descent were 
screened for 9 mutations (R1443X, 2953del3+C, 3768insA, W321X for BRCA1; 
8765delaG, E1953X, 3398del5, 2816insa, 6503delTT for BRCA2). Of the 301 
index cases corresponding to our inclusion criteria, 69 were identified as mutation 
carriers. Of these 69 carriers, 57 were found to carry a mutation from the f c panel 
(82.6%). The remaining 12 had a mutation identified by sequencing (17.4%), and 
5 of these mutations (2080insA, 2244insA, 2800delAA for BRCA1; 3773delTT, 
r2336H for BRCA2) were reported in at least 2 distinct families. By adding these 
mutations to our in-house panel, our detection rate will reach 97.1% (67/69).
Conclusions: This retrospective review of our laboratory data indicates 
that the detection rate of our in-house f c panel of 9 mutations is 82.6%. By 
adding 5 mutations, this detection rate will reach 97.1%. These preliminary 
data indicate that testing using the f c panel in appropriate families continues to 
be a cost-effective initial screening. The data are insufficient to preclude further 
testing by sequencing in panel-negative families. a periodic review of mutations 
identified by sequencing in f c families is important to improve and validate the 
efficiency of the f c panel.
The Characterization of Genomic Instability in Lymphoblastoid 
Cell Lines Derived from heterozygous PALB2 Mutation Carriers
D.J. Novak,*†‡ L. Amrein,‡ J. Reddy,§ L. Wark,§ R. Aloyz,*‡ S. Mai,§ 
M.D. Tischkowitz.*†‡ *Program in Cancer Genetics, †Medicine and 
Human Genetics, and ‡Segal Cancer Center, McGill University, 
Montreal, Quebec, and §Institute of Cell Biology, University of 
Manitoba, Winnipeg, Manitoba, Canada.
Objectives: PALB2, upon interaction with its nuclear partner, the breast 
cancer gene, BRCA2, is known to promote localization and stability. PALB2 is 
estimated to confer a moderately increased risk for breast cancer, likely because 
of a disruption of genomic regulation. To date, the underlying pathogenesis 
of PALB2 mutations has yet to be illuminated by common molecular 
mechanisms. It has previously been suggested that Fanconi anemia proteins, 
a group of which PALB2 is a member, may play a critical role in the telomere 
maintenance pathway, because of their core function in genetic recombination. 
In the current study, we attempt to establish both a molecular and cellular link 
between PALB2 heterozygous mutations and genomic instability, an important 
precursor to carcinogenesis.
Methods: Six lymphoblastoid cell lines (l c l s) were analyzed in the current 
study, two expressing wild-type PALB2, and four carriers of distinct heterozygous 
PALB2 truncating mutations: 2521dela, 3323dela, Q775X, and 229delT. Genomic 
integrity was assessed by telomeric quantitative fluorescence in situ hybridization 
(q-f i s h). Further investigations of genomic abnormalities were conducted through 
the use of centromeric f i s h and spectral karyotyping. The response to cellular 
cytotoxicity was examined in the presence of mitomycin C, bleomycin, and 
cisplatin. Cellular survival was measured via photo spectrophotometry through 
the metabolism of the tetrazolium salt WST-1.
Results: No statistical difference was observed in telomere number or 
median telomeric intensity between the two PALB2 control lines (C1 and C2, p = 
0.287). Similarly no significant differences were observed in telomere number 
or intensity between C1/C2 and the 3323delA carrier (p = 0.386 vs. C1 and p = 
0.786 vs. C2). Probe intensity was markedly reduced in the 2521delA carrier as 
compared with both C1 and C2. The Q775X carrier was observed with a reduced 
telomere count and differed significantly from either control with respect to 
mean probe intensity (p = 2.22–12 vs. C1 and p = 8.52–15 vs. C2). Similarly, the 
229delT carrier was observed with an increased telomere count and significantly 
differed in mean probe intensity (p = 6.05–17 vs. C1 and p = 1.77–12 vs. C2). No 
significant differences were observed in centromere number throughout all six 
l c l s. No duplications, translocations, deletions, or rearrangements were observed 
to be consistent with the pathogenicity of the PALB2 variants. No l c ls showed 
any significantly altered response to any of the cytotoxic agents.
Conclusions: The current study may suggest a possible association between 
PALB2 heterozygous truncating mutations and impaired genomic regulation. 
However, a new model system for analysis, such as a PALB2 tumour cell line, 
is required to further elucidate this potential association.
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Frequency of French-Canadian (FC) BRCA1/2 Common Founder 
Mutations in FC hereditary Breast/Breast and Ovarian Families 
Evaluated in Ottawa, Ontario
E. Smith, E. Tomiak, K. Teed, E. McCready, N. Carson. Children’s 
Hospital of Eastern Ontario, Ottawa, Ontario, Canada.
Objectives: Previous research has demonstrated that most BRCA1/2 
mutations (84%) detected in French-Canadian (f c) hereditary breast or breast/
ovarian cancer families living in Quebec are accounted for by 1 of 8 recognized 
common founder mutations (Tonin et al. Bull Cancer 2006:93:841–6). The 
objective of our study was to describe the pattern of BRCA1 and 2 mutations 
identified by the Molecular Genetics Laboratory of the Eastern Ontario Regional 
Genetics department located in Ottawa, Ontario.
Methods: Between april 1998 and May 2009, a retrospective chart review 
was conducted to obtain ethnicity data in women identified to carry a pathogenic 
BRCA1/2 mutation. The charts of 112 index cases were available for review. 
In 22 individuals, information regarding ancestry was missing or ancestry was 
unknown, leaving 90 cases available for analysis. All cases represented the first 
family member to be tested in our laboratory and found to carry a pathogenic 
mutation.
Results: The f c founder mutations were identified in 13/15 (86.7%) of 
families whose ethnicity was identified as f c and in additional 8/12 families where 
ancestry was considered to be probably or possibly f c. among the 22 families with 
missing/unknown ancestry, an additional 2 f c founder mutations were identified, 
for a total of 23 index cases found to carry a common f c founder mutation.
Conclusions: Our findings in a regional laboratory which serves both 
Franco-Ontarians and Québécois francophones parallel the demonstration of a 
limited spectrum of pathogenic BRCA1/2 mutations in Quebec patients previously 
reported by Tonin et al. The high percentage of cases accounted for by a limited 
panel of 8 common founder mutations suggests that consideration be given in 
Ontario to the evaluation of initial screening with a mutation panel in patients 
of French-Canadian ancestry.
Establishing the Evidence Base to Translate PALB2 Mutation 
Testing into Breast Cancer Clinical Genetics Services
M. Southey,* M. Tischkowitz,†‡ Z.L. Teo,* F. Odefrey,* N. Sabbaghian,† G. 
Byrnes,§ I. Winship,* b C f r,†† kConFab,‡‡ M. McCredie,|| G. Giles,# D. Goldgar** 
W. Foulkes,† J. Hopper.* *The University of Melbourne, Victoria, Australia; 
†McGill University and ‡Sir Mortimer B. Davis Jewish General Hospital, 
Montreal, Quebec, Canada; §The International Agency for Research on Cancer, 
Lyon, France; ||The University of Otago, Dunedin, New Zealand; #The Cancer 
Council Victoria, Victoria, Australia; **University of Utah School of Medicine, 
Salt Lake City, Utah, U.S.A.; ††Breast Cancer Family Registry, National Cancer 
Institute, National Institutes of Health, Bethesda, Maryland, U.S.A.; and ‡‡Peter 
MacCallum Cancer Centre, Victoria, Australia.
Mutations in PALB2 have been reported to be associated with a doubled to tripled 
increased risk of breast cancer. Women with mutations in PALB2 who also have a 
strong family history of breast cancer are predicted to be at a high absolute risk for the 
disease comparable to that in women who carry BRCA2 mutations. a current paucity 
of information about PALB2 mutation carrier risks prevents testing for mutations in 
this gene being incorporated into evidenced-based clinical genetics services.
Objectives: To conduct a large case–control family study using population-based 
and clinic-based resources, to characterize PALB2 mutations in terms of breast cancer 
risk, and to devise criteria to identify women most likely to carry PALB2 mutations.
Methods: High-resolution melt curve analysis and Sanger sequencing.
Results: To date, we have screened 756 early-onset population-based cases for 
PALB2 mutations and identified 2 carriers, both in women with extremely strong family 
histories of breast cancer. We have also screened 400 women from multiple-case breast 
cancer families and identified 4 families that carry PALB2 mutations. Testing for these 
mutations in relatives has identified an additional 20 PALB2 mutation carriers. Breast 
cancers arising in affected female carriers are commonly grade 3 (7/12 reviewed to 
date) and estrogen receptor–positive (7/9 reviewed to date); 9 are infiltrating ductal 
carcinomas, and 3 are lobular or pleomorphic lobular carcinomas.
Conclusions: We and others have produced preliminary and circumstantial 
evidence that women who carry a mutation in PALB2 are at an elevated risk of 
breast cancer, and that depending on family history, these risks could be of clinical 
relevance comparable to that for women with BRCA2 mutations. PALB2 mutations 
are rare, but for the women who carry these mutations and their families, it is 
potentially important that mutations be identified so that the women can be offered 
appropriate prevention, screening, and clinical management.
Recurrent BRCA1	Mutations	Identified	in	Manitobans	of	Eastern	
European Descenta
E. Spriggs,*†‡ T. Dyck,* R. Jobse,* B. Chordirker†‡§ A. Chudley†‡§ S. 
Marles†‡§ K. Serfas,§ Julie Richer.|| *Clinical Biochem and Genetics, 
Diagnostic Services of Manitoba; †Department of Biochemistry and 
Medical Genetics and ‡Department of Pediatrics and Child Health, 
University of Manitoba; and §Genetics and Metabolism Program, 
Winnipeg Regional Health Authority, Winnipeg, Manitoba; and 
||Medical Genetics, Children’s Hospital of Eastern Ontario, Ottawa, 
Ontario, Canada.
approximately 1 in 5 people living in the Canadian province of Manitoba 
are of Eastern European descent, with Ukraine being the most frequently 
named country of origin. Mutations in BRCA1 and BRCA2 account for most 
hereditary breast and ovarian cancers. Ten years ago, testing for BRCA1 and 
BRCA2 mutations in Manitoba was limited to the three common mutations 
found in the ashkenazi Jewish population, and shortly thereafter included 
screening by protein truncation testing. Through results obtained in-house 
and from published data, it became recognized that one of the three common 
mutations, BRCA1 c.5266dupC (5382insC), was also common in individuals 
of European descent, particularly those from Eastern Europe. Twelve unrelated 
Manitoban families were identified with the c.5266dupC mutation over the 
first 8 years of BRCA1 and BRCA2 genetic testing in Manitoba, and of these, 
only 4 (30%) are from families of Ashkenazi Jewish descent. The remaining 
cases were found in families reported to be of Ukrainian (n = 5), Polish (n = 
1), Hungarian (n = 1), and German/unknown (n = 1) descent, with no known 
Jewish background. Given this observation and the relatively high proportion 
of the Manitoba population being of Eastern European descent, an ethnic-
specific panel targeted to individuals of Eastern European descent was created. 
It included three BRCA1 mutations (c.5266dupC, p.Cys61Gly, c.4034delA) that 
were described in literature as “recurrent” for this population. Over the past 3 
years, 55 Manitobans have been tested, and two new families with mutations 
in BRCA1 were found, one with c.5266dupC and one with p.Cys61Gly. The 
c.5266dupC case, representing our 13th family, was identified in a woman of 
Ukrainian/German Mennonite descent who had bilateral breast cancer. The 
p.Cys61Gly was found in a Ukrainian family with a history of breast and ovarian 
cancer. A second unrelated family of Ukrainian descent was identified with the 
p.Cys61Gly mutation through denaturing high-pressure liquid chromatography 
mutation scanning of the BRCA1 and BRCA2 genes. as part of our full screen 
available to affected patients who meet our testing criteria for BRCA1 and 
BRCA2, a novel and yet recurrent BRCA1 genomic deletion involving exons 
13 through 19 was identified in 3 unrelated Manitoban families, with Ukrainian 
descent being the only common theme. data accumulated thus far suggest that 
the founder BRCA1 mutations for Manitobans of Eastern European descent are 
similar to those described by others, c.5266dupC and p.Cys61Gly, and that this 
unique in-frame deletion involves exons 13–19.
a  Published in Genetics in Medicine [In press].
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Identification	of	a	BRCA2 Founder Mutation in the Manitoba 
Mennonite Populationb
E. Spriggs,*†‡ K. Serfas,§ S. Burgess,* B. Chodirker†‡§ A. Chudley†‡§ S. Marles,†‡§ 
T. Dyck.* *Clinical Biochem and Genetics, Diagnostic Services of Manitoba; 
†Department of Biochemistry and Medical Genetics and ‡Department of 
Pediatrics and Child Health, University of Manitoba; and §Genetics Program, 
Winnipeg Regional Health Authority, Winnipeg, Manitoba, Canada.
The Mennonites are a distinct ethnic and religious group characterized by 
their Anabaptist beliefs and pacifism. Over the last few centuries, persecution forced 
this group to migrate throughout Northern and Eastern Europe, and then to Southern 
Manitoba (Canada), the American Midwest, Mexico, and Central and South America. 
There are about 66,000 Mennonites residing in the Canadian province of Manitoba, 
accounting for approximately 6% of its total population. Founder mutations have 
been identified in the Mennonite population for a number of genetic diseases, 
including hypophosphatasia, X-linked congenital stationary night blindness, and 
familial hypertrophic cardiomyopathy. We have identified a mutation, c.5238dupT 
(p.Asn1747fs), in the BRCA2 gene in 4 unrelated Mennonite families. The index 
patients were referred for genetic testing of BRCA1 and BRCA2 genes because of 
personal and family histories of breast and ovarian cancer. One family also had a 
history of pancreatic cancer. Of the 4 families, 3 were long-time residents of Manitoba; 
1 family had recently emigrated from Bolivia. Further investigations into the pedigrees 
did not reveal any common relatives between the families. These mutations were 
independently identified by d n a  sequencing following the observation of a truncated 
band using the protein truncation test targeted to exon 11 of BRCA2. The c.5238dupT 
mutation has been reported only a limited number of times in the Breast Cancer 
Information Core database and in the literature, and it has been restricted to patients 
of dutch, German, Mennonite, and Western and Eastern European descent. The 
finding of 4 large pedigrees of Mennonite descent indicates the presence of a founder 
mutation in the Manitoba Mennonite population. The population frequency of this 
BRCA2 c.5238dupT mutation among Manitoba Mennonites is not known, but it may 
be of value to offer targeted mutation analysis to individuals of Mennonite descent 
who have a personal and/or family history of breast and ovarian cancer. However, it 
is important to note that other mutations, such as BRCA2 c.6952C>T (p.Arg2318X), 
have been identified in Manitoba Mennonites with strong family histories of cancer. 
Such families that meet testing criteria and do not carry the c.5238dupT mutation 
should be offered full screening for BRCA1 and BRCA2.
b  Published in Genetics in Medicine [In press].
The Breast Cancer Genes International Agency for Research on 
Cancer Database: A Tool to Improve Evaluation of BRCA1 and 
BRCA2	Unclassified	Sequence	Variants
M. Vallee,* F. Lesueur,* A. Spurdle,† F. Hogervorst,‡ D.E. Goldgar,§ 
S.V. Tavtigian.* *International Agency for Research on Cancer, 
Lyon, France; †Queensland Institute of Medical Research, Herston, 
Queensland, Australia; ‡The Netherlands Cancer Institute, Amsterdam, 
Netherlands; and §University of Utah School of Medicine, Salt Lake 
City, Utah, U.S.A.
BRCA1 and BRCA2 are the two major high-risk breast cancer susceptibility 
genes, and the scale of clinical mutation screening of these genes probably 
exceeds that of any other set of cancer susceptibility genes. One complication 
resulting from genetic testing is that between 5% and 15% of patients screened 
are found to carry an unclassified sequence variant (u v ). Observations of u v s 
create problems for the clinical lab staff who initially detect the u v s through to 
the patients who receive the ambiguous information.
The Breast Cancer Information Core has developed a Bayesian integrated 
evaluation of u v s based on co-segregation, personal and family history, tumour 
histopathology, and co-occurrence of variants in trans. Integrated evaluation 
includes a prior probability based on these in silico analyses of the substitutions, 
both from the perspective of potential effects on mr n a  splicing and potential 
effects on protein function. To facilitate the evaluation of BRCA1 and BRCA2 
u v s, we created the BrCa International agency for research on Cancer 
(i a r c ) database. This database contains the set of all possible single nucleotide 
substitutions (which constitute a sizeable preponderance of all u v s) to the open 
reading frames of BRCA1 and BRCA2. In silico analysis programs can be run 
on this finite set. The BRCA i a r c  database summarizes predicted potential to 
interfere with mr n a  splicing (MaxEnt and NNSplice) and predicted missense 
substitution severity (position and Align-GVGD, using curated protein multiple 
sequence alignments) on the entire set. These scores are integrated to give a prior 
probability of pathogenicity for each substitution. Thus the database, and the Web 
site through which we present it (brca.iarc.fr/), provides a starting point for the 
integrated evaluation of most BRCA1 and BRCA2 u v s.
Pathogenicity of the BRCA1 Missense Variant D1739V Supported 
by Multiple Lines of Evidence
R.B. van der Luijt,* A.N.A. Monteiro,† A.Y. Bronkhorst,* T.G.W. Letteboer,* 
C.J.M. van der Sijs–Bos,* J.G. Post,* R. Karchin,‡ S.V. Tavtigian,§ D.E. 
Goldgar,|| P.M. Nederlof,# H.K.P. van Amstel.* *Department of Medical 
Genetics, University Medical Center, Utrecht, Netherlands; †H. Lee Moffitt 
Cancer Center and Research Institute, Tampa, Florida, and ‡Department of 
Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, 
U.S.A.; §International Agency for Research on Cancer, World Health 
Organization, Lyon, France; ||Department of Dermatology, University of 
Utah School of Medicine, Salt Lake City, Utah, U.S.A.; and #Department of 
Pathology, Netherlands Cancer Institute, Amsterdam, Netherlands.
Objectives: The clinical relevance of most non-truncating mutations in the 
BRCA1 and BRCA2 genes, including amino acid substitutions, is unknown. The 
assessment of these unclassified variants (u v s), which is of crucial importance 
for appropriate risk management, requires a multimodal approach.
Methods: By integrating classical genetic, tumour histopathologic, functional, 
evolutionary conservation, and computational approaches, we investigated the 
pathogenic nature of a missense mutation, D1739V (c.5216A>T, p.Asp1739Val), 
of the BRCA1 gene identified in 2 of our breast/ovarian cancer families.
Results: The d1739V variant showed complete co-segregation in both 
families, loss of the wild-type BRCA1 allele with retention of the variant allele 
in tumour-derived d n a , a BRCA1-like genomic profile in a breast tumour from 
an u v  carrier, and loss-of-function in transcriptional activity assays. d1739 is 
located within the b r c t  domain of BRCA1. a protein multiple sequence alignment 
containing 13 BRCA1 orthologs from different species showed complete 
evolutionary conservation of d1739. Computational analysis using the align-
GVGD method classifies D1739V as highly likely to interfere with normal protein 
function, based on the evolutionary conservation of d1739 and physicochemical 
characteristics of the amino acid pair d and V. The functional impact of the 
d1739V variant was also analyzed by three supervised learning programs, all 
predicting a deleterious effect. Protein modeling of the b r c t  domain of BRCA1 
suggested that d1739V disrupts the conformational stability of this domain.
Conclusions: all types of data generated in this study support a pathogenic 
nature of the variant d1739V, and we therefore propose to classify this amino 
acid substitution as a deleterious BRCA1 mutation.
hereditary Breast/Ovarian Cancer and BRCA Mutations: A South 
African Perspective
N.C. van der Merwe,*† E. Jansen van Rensburg.‡ *University of the Free 
State and †National Health Laboratory Services, Bloemfontein, Free 
State; and ‡University of Pretoria, Pretoria, Gauteng, South Africa.
Objectives: Breast cancer is the most common cancer to affect South 
african women, with a lifetime risk of 1 in 13 for the afrikaner. discovery of the 
BRCA genes introduced a new era for genetic testing, for not only could affected 
patients be informed regarding their risk for other cancer types, but other at-risk 
relatives could also be identified. The discovery of these genes urged many 
countries, including South africa, to launch investigations into the prevalence 
of mutations in these genes.
Methods: a total of 157 afrikaner breast and/or ovarian cancer families 
(≥3 cases) were screened using conventional polymerase chain reaction analyses. 
Families carrying identical mutations were genotyped to determine whether the 
mutations resulted from independent events or a common ancestor. a genetic 
counselling protocol, based on classical clinical counselling strategies, was 
developed for patients requesting testing.
Results: BRCA1 mutations accounted for 19% (30/157) and BRCA2 
mutations for 47% (73/157) of mutation-positive families. Three recurrent 
mutations were identified, two in BRCA1, 1493delC and E881X, and one in BRCA2, 
8162delG. Genotype and genealogical analyses indicated common ancestors, with a 
specific European founding couple identified for each. Collectively, the 3 Afrikaner 
founder mutations accounted for 94% (97/103) of BRCA mutation-positive 
families. a diagnostic testing protocol has since been implemented. Because of 
incomplete penetrance, preliminary investigations into potential single-nucleotide 
polymorphisms revealed that homozygosity for the variant allele of WAF1 
IVS2+16C→G proved to be associated with an increased breast cancer risk among 
BRCA2 mutation carriers affected with breast cancer specifically.
Conclusions: The 3 founder mutations are unique and limited to the South 
african afrikaner population. The uniqueness could possibly be attributable to 
both mutations being de novo occurrences in one of the founders; or the particular 
mutations might be extremely rare in the European populations from which the 
forefathers originally came; or lastly, both mutations were initially present in the 
European populations, but have become extinct.
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Frequency of the c.1100delC CHEK2 Mutation in a Cohort of 
Belgian Familial Breast Cancer Patients: The Leuven Experience
G. Michils, M. Chmara, G. Matthijs, E. Legius. Center for Human 
Genetics, University of Leuven, Leuven, Belgium.
Nowadays genetic testing for hereditary breast cancer is offered worldwide. 
In about 20% of familial cases, the disease-causing mutations can be identified; 
the rest remain unexplained. Many of these mutations occur in the high-penetrance 
breast cancer genes BRCA1 and BRCA2. a limited percentage are attributable to 
pathogenic mutations in moderate-penetrance genes such as CHEK2.
Objectives: In leuven, the familial cases are routinely tested for mutations 
in the BRCA1/2 genes. To study the involvement and the implications of the 
specific c.1100delC CHEK2 variant in breast cancer, a large cohort of affected 
patients has been tested for the presence of this mutation. The collected data have 
been analyzed and discussed for possible further clinical service.
Methods: The presence of the c.1100delC mutation was assessed by 
multiplex ligation-dependent probe amplification (P-045 MRC-Holland). The 
positive samples have been subsequently sequenced for confirmation.
Results: The frequency of the c.1100delC mutation in Belgian patients is 
3.4%—very close to the frequency found in the Netherlands. Compared with 
BRCA1/2 mutations, this CHEK2 mutation was more frequent in bilateral breast 
cancer patients and in patients with an age of onset over 46 years. Our data are also 
consistent with the observation that the CHEK2 gene is a multi-organ gene.
Conclusions: although the CHEK2 gene is a moderate-risk breast cancer 
gene, these data can be taken into account because of the implications for 
clinical practice. Given that the relative risk of breast cancer for CHEK2 by 
age 60 is 6%–10% (vs. 30%–60% for BRCA1/2), clinical follow-up for patients 
carrying the c.1100delC mutation has been adapted to become more stringent. 
The frequency of this mutation in Belgium warrants its implementation in the 
diagnostic service.
Clinical, Pathologic, and Genetic Characteristics of Chinese 
Patients with BRCA-Related Breast Cancer
A. Kwong,*†§ E.K.O. Ng,* C.L.P. Wong,†‡ E.S.K. Ma.†‡ *Division of 
Breast Surgery, The University of Hong Kong Li Ka Shing Faculty of 
Medicine, and †Cancer Genetics Centre and ‡Division of Molecular 
Pathology, Hong Kong Sanatorium and Hospital, Hong Kong SAR, 
PR China; and §Department of Surgery, Stanford University, Stanford, 
California, U.S.A.
Background: Breast cancers attributable to underlying germline BRCA1 
and BRCA2 mutations are associated with particular pathologic features that may 
differ from those of sporadic breast cancers. We report clinical and pathologic 
characteristics of breast cancer in Chinese women with and without mutations 
and of carriers of BRCA1 mutations as compared with BRCA2 mutations.
Methods: Based on age and family history, 226 high-risk women were 
recruited from March 2007 to November 2008. Medical information was 
prospectively collected from the patients and medical records. BRCA1 and 
BRCA2 mutations were detected using full gene sequencing and multiplex 
ligation-dependent probe amplification.
Results: Of the 226 female probands tested, 28 women (12.4%) were 
BRCA mutation carriers, and among these carriers, 11 (39.3%) had BRCA1 and 
17 (60.7%) had BRCA2 mutations. The BRCA mutation carriers were more likely 
to have a familial history of breast and ovarian cancer, high-grade cancers, and 
triple negative (t n) cancers. Prevalence of t n was 48.3% in BRCA carriers and 
25.6% in non-carriers; it was 67.7% in BRCA1 and 35.3% in BRCA2 carriers. 
Estrogen receptor–negative cancer was significantly associated with BRCA1 
mutations, especially in those under 40 years of age (odds ratio: 5.14; confidence 
interval: 1.03 to 25.60). In this cohort, one recurrent BRCA2 mutation was found 
in 4 probands, accounting for 23.5% of BRCA2 mutations and 14.3% of all BRCA 
mutations. The haplotype analysis confirmed the recurrent mutation c.3109C>T 
to be a founder mutation of Southern Chinese.
Conclusions: BRCA-related breast cancer in this Chinese population is 
associated with family history and adverse pathologic and prognostic features, 
with BRCA2 mutations being more prevalent, but BRCA1 carriers having more 
aggressive and t n cancers. Compared with Caucasian populations, the prevalences 
of BRCA2 mutations and t n cancer are elevated.
Genetic	Cancer	Risk	Modifiers	in	Hereditary	Breast	and/or	
Ovarian Cancer Families
R.D. Brandao,*† M.J. Blok,* J. van Harssel,* A. Romano,*† C. 
Schrander–Stumpel,*† J. Geraedts,*† M. Zeegers,*‡ E.B. Goméz 
García.*† *University Hospital of Maastricht and †GROW – School 
for Oncology and Developmental Biology, University Maastricht, 
Maastricht, Netherlands; and ‡School of Medicine, University of 
Birmingham, Birmingham, U.K.
Introduction: Variability observed in penetrance, age of onset, and site 
of the tumour, both among and within BRCA families, suggests that other low-
penetrance genetic variants modify the cancer risk.
Objectives: To study the effect of 6 polymorphisms, recently described 
as being risk modifiers of sporadic breast cancer (b c ) or ovarian cancer (o c ) in 
BRCA families.
Methods: We recorded the cancer history (tumour site, age of diagnosis) 
of 548 women (293 carriers, 255 non-carriers) from 125 BRCA families (72 
BRCA1, 53 BRCA2). The polymorphisms genotyped were: +331G/A and p r o g i n s , 
localized in the progesterone receptor gene, CASP8 d302H, CASP8–652 6Nins/
del, FGFR2 (rs2981582), and TNRC9 (rs3803662). Familial clustering was taken 
into account in the statistical analyses.
Results: Two polymorphisms modified the risk of o c  in BRCA1 and BRCA2 
families: +331 G/A heterozygous genotype increased the risk [odds ratio (o r ): 
2.41; 95% confidence interval (c i ): 0.98 to 5.96; p = 0.056], and FGFR2 had a 
protective effect (o r : 0.52; 95% c i : 0.28 to 0.96; p = 0.037). FGFR2 was also 
significantly associated with increased risk of bilateral b c  (o r : 2.67; 95% c i : 
1.45 to 4.92; p = 0.002), whereas CASP8–652 6Nins/del had a trend toward a 
protective effect, restricted to BRCA1 mutation carriers (o r : 0.71; 95% c i : 0.48 
to 1.05; p = 0.084). Furthermore, p r o g i n s  was significantly associated with b c  
among the BRCA2 non-carriers (phenocopies—o r : 8.17; 95% c i : 2.17 to 30.76; 
p = 0.002).
Conclusions: We found evidence that certain polymorphisms involved 
in hormone-mediated cell proliferation and apoptosis modify the b c  and o c  
risks in BRCA families. This may be relevant for an individual assessment of 
the most suitable preventive option among those currently available for each 
of those patients.
Genome-Wide Linkage Analysis of high-Risk Breast Cancer 
Families from the International BRCA-X Consortium
M. Southey,*† F. Odefrey,*† B. Feng,‡ G. Mann,§ P. Devilee,|| D. 
Goldgar.*‡ *Melbourne University, Melbourne, Victoria, Australia; 
†International Agency for Research on Cancer, Lyon, France; 
‡University of Utah School of Medicine, Salt Lake City, Utah, U.S.A.; 
§Westmead Institute of Cancer Research, Sydney, Australia; and 
||Leiden University Medical Center, Leiden, Netherlands.
although studies have shown that germline mutations in BRCA1 and 
BRCA2 account only for approximately half of all site-specific familial breast 
cancer (b c ), to date there has been little success in using a linkage approach to 
identify further b c  susceptibility loci. Thus, it seems likely that there are additional 
high-penetrance loci to be discovered. In 2006, we published the results of a 
linkage analysis in 149 multiple-case b c  pedigrees. although several regions 
of interest were identified, no definitive evidence of linkage was found, likely 
because of genetic heterogeneity. To address this, we have now analyzed a further 
set of 123 families that were part of an international consortium in familial b c  
including families from North America (n = 53), Europe (n = 57), and Australia 
(n = 14). All families had at least 3 cases of b c  diagnosed at or before the age 
of 60 and were previously screened for mutations in BRCA1 and BRCA2. The 
primary analysis used m e r l i n under a dominant mode of inheritance using the 
same model as in Smith et al., 2006.
Results: The linkage analyses identified one region with a conditional 
heterogeneity logarithm of odds (h l o d ) of 2.2, and three others with h l o d s > 1.0. 
In a combined analysis of the new and existing data, suggestive evidence of 
linkage was identified on chromosome 4 (h l o d  = 2.4, α = 0.15). When families 
were stratified by the presence of bilateral b c  or of 5 or more cases of b c , the 
evidence (or the linkage) was increased (h l o d  = 3.3, α = 0.30 and h l o d  = 3.6, α = 
0.26 respectively). To further refine the hypothesized locus on chromosome 4, we 
genotyped a further 12 short tandem repeat markers spanning the linked region. 
Fine mapping of likely-linked families has narrowed the region likely containing 
a b c  susceptibility gene to 14.6 cM covering approximately 18 Mb of d n a . We are 
currently sequencing the most plausible candidate genes within this region.
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Genetic Variation of human MDM4 Confers Increased Risk for 
Breast Cancer in the Ashkenazi Jewish Populationc
V. Joseph,* M. Gaudet,* V. Devlin,* J. Bhatia,* K. Kosarin,* G. 
Bond,† K. Offit,* T. Kirchhoff.* *Memorial Sloan–Kettering Cancer 
Center, New York, New York, U.S.A., and †Ludwig Institute for Cancer 
Research, Oxford, U.K.
The t p53 tumour-suppressor pathway plays a critical role in the progression 
of a variety of human cancers. among the known regulators, MDM4, a 
haploinsufficient homologue of MDM2, has been shown to bind and inhibit t p53 
protein. as part of a candidate t p53 pathway approach, a statistically significant 
association with breast cancer (b c ) risk was observed at the MDM4 locus in 
our recent genome-wide association study (g wa s ) in the Ashkenazi Jewish (a j ) 
population. We observed a large extent of linkage disequilibrium around the 
MDM4 locus in a j  b c  cases from our a j  g wa s , with multiple single-nucleotide 
polymorphisms (s n p s) significantly associated with b c  risk. analysis of these 
data revealed a susceptible haplotype and a modestly elevated b c  risk [p = 0.01; 
odds ratio (o r ): 1.2; 95% confidence interval (c i ): 1.01 to 1.45]. To replicate 
these findings, we genotyped a tagging s n p  for this haplotype (rs2369244) in 
independent collections of 654 a j  b c  cases and 1085 a j  controls. Similar to the 
findings in the g wa s  cohorts, the minor allele homozygotes were significantly 
enriched in cases as compared with controls (p = 0.01; o r : 1.19; 95% c i : 1.04 
to 1.38). Furthermore, a pooled meta-analysis including the g wa s  data (total of 
1133 b c  cases and 1351 controls), and controlling for age, suggests that this s n p  
significantly associates with b c  risk in a j  population. The association was most 
apparent for minor allele homozygotes (G/G—o r : 1.52; 95% c i : 1.18 to 1.95; p = 
0.00085). Further replication analysis is being planned as part of an international 
Breast Cancer association Consortium involving more than 60,000 b c  cases 
and controls of predominantly European ancestry. Besides ongoing functional 
experiments, the next phase of the study will address possible gene–gene 
interactions of MDM4 rs2369244 with other critical players in this pathway, 
including MDM2 s n p 309 and TP53 r72P, where genetic variation has also been 
described to be associated with increased risks for other cancer types.
c  Published in Proc Natl Acad Sci U S A 2009;106:10236–41.
Rare, Evolutionary Unlikely Missense Substitutions in ATM 
Confer Increased Risk for Breast Cancer
S.V. Tavtigian,* A. Hartmann,† S. Healey,‡ F. Le Calvez–Kelm,* F. 
Lesueur,* D. Babikyan,* G.B. Byrnes,* J. Hall,§ S. Sangrajrang,|| J.L. 
Hopper,# M.C. Southey,# I.L. Andrulis,** E.M. John,†† P.J. Oefner,† G. 
Chenevix–Trench.‡ *International Agency for Research on Cancer, Lyon, 
France; †Institute of Functional Genomics, University of Regensburg, 
Regensburg, Germany; ‡Queensland Institute of Medical Research, 
Brisbane, Australia; §Institut Curie, Recherche, INSERM U612, Orsay, 
France; ||National Cancer Institute, Research Division, Bangkok, 
Thailand; #Centre MEGA Epidemiology, University of Melbourne, 
Carlton, Victoria, Australia; **Cancer Care Ontario and Mount Sinai 
Hospital, Toronto, Ontario, Canada; and ††Northern California Cancer 
Center, Fremont, California, U.S.A.
The susceptibility gene for ataxia telangiectasia, ATM, is also an intermediate-
risk breast cancer susceptibility gene. However, the spectrum and frequency 
distribution of ATM mutations that confer increased risk of breast cancer have 
been controversial. To assess the contribution of rare variants in this gene to risk 
of breast cancer, we pooled data from seven published ATM case–control mutation 
screening studies including a total of 1544 breast cancer cases and 1224 controls 
with data from our own mutation screening of an additional 987 breast cancer cases 
and 1021 controls. Using an in silico missense substitution analysis that provides 
a ranking of missense substitutions from evolutionarily most likely to least likely, 
we carried out analyses of protein-truncating variants, splice junction variants, 
and rare missense variants. We found marginal evidence that the combination of 
ATM protein-truncating and splice junction variants contribute to breast cancer 
risk. There was stronger evidence that a subset of rare, evolutionarily unlikely 
missense substitutions confer increased risk. On the basis of subset analyses, we 
hypothesize that rare missense substitutions falling in and around the f a t , kinase, 
and f a t c  domains of the protein may be disproportionately responsible for that 
risk, and that a subset of these may confer higher risk than do protein-truncating 
variants. We conclude that a comparison between the graded distributions of 
missense substitutions in cases versus controls can complement analyses of 
truncating variants to help identify susceptibility genes, and that this approach will 
help interpret the data emerging from new sequencing technologies.
A Mouse Model Reveals a Possible Function for BRCA1 in human 
Uterine Leiomyosarcoma
D. Xing,* G. Scangas,* M. Nita,* X. Xu,† L. He,* Y.J.M. Ioffe,† P.J. 
Aspuria,† C.Y. Hedvat,‡ M.L. Anderson,§ E. Oliva,*|| B.Y. Karlan,† 
G. Mohapatra,* S. Orsulic.*†|| *Massachusetts General Hospital, 
Boston, Massachusetts; †Cedars–Sinai Medical Center, Los Angeles, 
California; ‡ Memorial Sloan–Kettering Cancer Center, New York, 
New York; §Baylor College of Medicine, Houston, Texas; and ||Harvard 
Medical School, Boston, Massachusetts, U.S.A.
Uterine leiomyosarcoma (u l m s ) is a rare gynecologic malignancy with a 
low survival rate. Currently, there is no effective treatment for u l m s . Infrequent 
occurrences of human u l m s  hamper the understanding of the initiation and 
progression of the disease, thereby limiting the ability to develop efficient 
therapies. To elucidate the roles of the p53 and BRCA1 tumour suppressor genes 
in gynecologic malignancies, we generated mice in which p53 and/or BRCA1 
can be conditionally deleted using anti-Müllerian hormone type ii receptor 
(Amhr2)–driven Cre recombinase. Mice with a conditional deletion of p53 
developed uterine tumours that resembled human u l m s . a concurrent deletion of 
p53 and BRCA1 accelerated the progression of those tumours. Consistent with 
the hypothesis that BRCA1 plays a role in u l m s , we have shown that the BRCA1 
protein is absent in 29% of human u l m s . We have demonstrated that BRCA1 
promoter methylation is the likely mechanism of BRCA1 downregulation in 
human u l m s . Our findings provide a rationale for investigating therapies that 
target BRCA1 deficiency in u l m s .
Morphologic and Immunohistochemical Correlation of Ovarian 
Epithelial Dysplasia in Prophylactic Oophorectomies from 
BRCA1/2 Mutation Carriers
G. Chêne,* J. Dauplat,† N. Lagarde,* P. Jaffeux,‡ Y.J. Bignon,§ F. 
Penault–Llorca.* *Service d’anatomopathologie and †Service de 
Chirurgie, Centre Jean Perrin; ‡Département d’Information Médicale, 
CHU Gabriel Montpied; and §Laboratoire d’Oncologie Médicale, 
Centre Jean Perrin, Clermont–Ferrand, France.
Objectives: Histopathologic examination of material from prophylactic 
salpingo-oophorectomies performed in patients at genetic risk has revealed 
frequent abnormalities interpreted as possible pre-cancerous “ovarian dysplasia” 
lesions. We sought to study the morphologic features and immunohistochemical 
expression patterns of neoplasia-associated markers in prophylactically removed 
ovaries.
Methods: Morphologic features and immunohistochemical expression 
patterns of Ki-67, p53, and a l d h 1 (an enzyme significantly associated with 
early-stage ovarian cancer) were evaluated in 35 prophylactic oophorectomies 
from BRCA1/BRCA2 carriers and 62 normal ovaries. representative slides from 
formalin-fixed, paraffin-embedded tissue blocks were all read blindly by two 
gynecologic pathologists. Immunohistochemical staining results were correlated 
with morphologic findings.
Results: Mean dysplasia score was significantly higher in the genetic risk 
group than in controls (9.55 vs. 3.62, p < 0.0001). Increased a l d h 1 expression 
was observed in prophylactically removed ovaries compared with normal ovaries, 
and expression patterns of Ki67 and p53 were low in both groups.
Conclusions: The increased dysplasia score and a l d h 1 expression in 
ovaries from BRCA1/2 carriers might be consistent with progression towards 
neoplastic transformation and could justify the use of the term “dysplasia” or 
intraepithelial ovarian neoplasia. Ovarian dysplasia may be a pre-malignant, 
noninvasive histopathologic abnormality that could be an important step in early 
neoplasia, especially in ovaries from BRCA1/2 carriers.
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Screening and Prevention Utilization in Unaffected BRCA Carriers
M. Beattie,*† T. Yu,* B. Crawford,* M. Metrikin,† R. Lee.† *University 
of California and †San Francisco General Hospital, San Francisco, 
California, U.S.A.
Objectives: The purpose of this research is to carefully quantitate the 
uptake of screening breast magnetic resonance imaging (m r i ), chemoprevention, 
risk-reducing mastectomy (r r m), and risk-reducing salpingo-oophorectomy 
(r r s o ) in unaffected BRCA carriers. We also aim to compare predictors of each 
of these options.
Methods: We thoroughly surveyed all women who received BRCA 
counselling and testing at University of California–San Francisco in the last 15 
years. Using the 2008 Cancer risk Program survey, BRCA testers were queried 
regarding screening and preventive options, risk perception, cancer worry, 
knowledge, and opinions regarding screening and prevention.
Results: The survey response rate was more than 80%, with 1137 returns. 
approximately 20% of this population tested positive for a known deleterious 
BRCA mutation, and about half of the BRCA positives were unaffected with 
breast or ovarian cancer. Of the 102 unaffected BRCA carriers, 66 had BRCA1 
mutations, and 36 had BRCA2 mutations. Their median age was 38 years (range: 
20–64 years). Risk-reducing mastectomy was chosen by 30% of these women, 
and r r s o was chosen by 58%. The median time between BRCA testing and 
undergoing a risk-reducing surgery was 5 months. Of women with breast tissue 
at risk, 73% received screening breast m r i , and 7% chose chemoprevention (3.5% 
with tamoxifen, 3.5% with raloxifene). Cancer screening knowledge did not differ 
between women choosing m r i , chemoprevention, or surgeries. Breast cancer risk 
perception was significantly lower in women who chose r r m  as compared with 
other options (p < 0.05), but cancer worry did not differ between option choices. 
as women aged, they tended to choose the following options, from younger to 
older age: m r i , r r m , r r s o , chemoprevention (p for trend < 0.05).
Conclusions: The uptake of screening breast m r i  in unaffected BRCA 
carriers in this cohort was higher by a factor of approximately 10 than was 
the uptake of chemoprevention. The median time to r r m  and r r s o , for women 
who chose those options, was quite short, at approximately 5 months. It is 
important to present unaffected BRCA carriers with a range of options for 
screening and prevention, understanding that there is a wide variation of uptake 
for each option.
Review of BRCA1 and BRCA2 Mutation Screening at Guy’s 
hospital, London, U.K.
J. Campbell,* H. Storey,* S. Lillis,* T. Cullup,* J. McCauley,* 
D. Moore,* C. Jacobs,† G. Pichert,† S.C. Yau,* S. Abbs.* *DNA 
Laboratory, GSTS Pathology, and †Clinical Genetics, Guy’s and 
St. Thomas’ NHS Foundation Trust, London, U.K.
In response to the 2004 U.K. National Institute for Health and Clinical 
Excellence Guidelines for Familial Breast Cancer, our screening strategy for 
the BRCA1 and BRCA2 genes was changed from screening approximately two 
thirds of each gene using a protein-truncation test and fluorescent heteroduplex 
analysis to a complete screen of both genes using sequencing and multiplex 
ligation-dependent probe amplification (m l p a ).
Since May 2006, we have screened 564 new referrals and have found 
BRCA1 or BRCA2 pathogenic mutations in 99 individuals (18%). A variant 
of unknown significance (v u s ) has been identified in a further 83 individuals 
(15%). We have also retrospectively completed a full screen on 738 individuals 
who previously had a negative two-thirds screen. This involved a significant 
collaboration with the Clinical Genetics Team who reviewed all individuals seen 
before January 2000 to ensure that they met current testing guidelines. In this 
group, BRCA1 or BRCA2 pathogenic mutations were identified in 45 individuals 
(6%), and a v u s  was identified in a further 48 individuals (7%). Of the 144 (65 
BRCA1, 79 BRCA2) pathogenic mutations identified, 127 (51 BRCA1, 76 BRCA2) 
were detected by sequencing, and 17 (14 BRCA1, 3 BRCA2) by m l p a . a total of 40 
BRCA1 mutations and 44 BRCA2 mutations have been seen in only 1 individual. 
Of the 11 BRCA1 and 12 BRCA2 mutations that have been identified more than 
once, most have been seen in only 2 unrelated individuals. However BRCA1 
c.4065_4068delTCaa has been seen in 4 unrelated individuals, duplication of 
BRCA1 exon 13 in 3 unrelated individuals, BRCA2 c.755_758delaCaG in 6 
unrelated individuals, and BRCA2 c.7988a>T in 5 unrelated individuals.
In total, 126 different v u s  have been identified, of which 101 have been 
seen in only 1 individual. These comprise 68 missense variants (23 BRCA1, 45 
BRCA2), 30 synonymous variants (13,17), and 28 intronic variants (8,20).
Significant	Differences	Among	Physician	Specialties	in	the	
Management of BRCA1 and BRCA2 Mutation Carriers
S. Dhar,* P. Cooper,* S. Hilsenbeck,* P.A. Kelly,* C. Noll,† T. Wang,* 
S. Plon.* *Baylor College of Medicine and †University of Texas Health 
Science Center, Houston, Texas, U.S.A.
Objectives: The National Comprehensive Cancer Network (n c c n ) has 
put forth practice guidelines for hereditary breast and ovarian cancer syndrome 
(h b o c s ) management. We here present data on how different physician specialties 
recommend surveillance for patients who have undertaken genetic testing.
Methods: We conducted an online survey of Texas a m a  physicians that 
included random sampling of 5 different specialties: family medicine (f m), 
obstetrics and gynecology (o g ), general surgery (g s ), internal medicine (im) and 
hematology–oncology (h o ). In 4 hypothetical case scenarios, the physicians were 
asked to handle h b o c s  management of unaffected women ages 40–42 years, in 
the presence of a familial mutation.
Results: The survey was completed by 23% of the physicians (n = 224). 
For BRCA-negative women, 42% of the physicians (with no clearly significant 
differences among specialties, p = 0.08) recommended surveillance as set 
forth by n c c n . Using an aggregate screening intensity score, physicians clearly 
recommended more screening for mutation-positive women than for mutation-
negative women; however, only about 3% followed n c c n  guidelines. For BRCA-
positive women, 89% of h o /o g  recommended breast m r i , compared with 63% of 
im/f m (p < 0.0001); 81% of g s /h o , as compared with 35% of im/f m, recommended 
prophylactic mastectomy (p < 0.0001); and 76% of g s /o g /h o , as compared with 
45% of im/f m, recommended prophylactic oophorectomy (p < 0.0001). Overall, 
physicians who had ordered BRCA testing in their practice recommended more 
intense management of mutation-positive women than did those that had not (p = 
0.0059 independent of their specialties) and management that was more intense 
than specified in the n c c n  guidelines (p = 0.0015).
Conclusions: although surveillance guidelines and prophylactic surgical 
options have been established for BRCA mutation carriers, many physicians are 
not cognizant of these guidelines, including the use of new imaging modalities and 
appropriate prophylactic surgery. Our study identifies a need to target education 
of physicians by specialty, so that optimal surveillance and management options 
can be offered to these high-risk women.
A Rare Case of Anal Melanoma in a BRCA1 Mutation Carrier
L. Dohany, W. Ducaine, D. Zakalik. Beaumont Hospital, Royal Oak, 
Michigan, U.S.A.
Objectives: Mutations in BRCA1 and BRCA2 are associated with an 
increased risk of breast, ovarian, prostate, and pancreatic cancer. There have 
been reports of a mild association of BRCA2 mutations with cutaneous and ocular 
melanoma. We present a rare case of an anal melanoma in a BRCA1 ashkenazi 
Jewish founder mutation carrier.
Methods: a 62-year-old male of ashkenazi Jewish descent presented with 
symptoms of anal pain and hematochezia. Sigmoidoscopy revealed an anal mass, 
and biopsy demonstrated invasive malignant melanoma of the anal canal. Staging 
work-up revealed liver metastases. Family history was significant for a sister who 
died at age 30 from breast cancer, and a 40-year-old daughter diagnosed with 
ovarian cancer at age 36 who tested positive for a BRCA1 mutation, 187delaG. 
The patient presented for genetic counselling and testing. The patient’s peripheral 
blood was sent for analysis of the three ashkenazi Jewish founder mutations: 
BRCA1 187delaG, BRCA1 5385insC, and BRCA2 6174delT.
Results: Molecular analysis identified a deleterious mutation, 187delAG, in 
the BRCA1 gene. This is a frameshift mutation that results in premature truncation 
of the BRCA1 protein at amino acid position 39. This confirms the diagnosis of 
hereditary breast and ovarian cancer syndrome (h b o c s ).
Conclusions: This case represents the first report of an anal melanoma in 
a BRCA1 carrier and sheds light on an unusual cancer presentation in patients 
with h b o c s . Earlier studies have shown an association between melanoma and 
BRCA2 mutations, but there has been little-to-no evidence of this association in 
BRCA1 carriers, especially carriers with ashkenazi Jewish founder mutations. 
detection of the BRCA1 187delaG mutation in this patient leads to promising 
therapeutic options using novel systemic agents for this highly aggressive, 
potentially lethal malignancy.
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A Rare Case of Ocular Melanoma in a BRCA1 Mutation Carrier
F. Khan, L. Dohany, W. Ducaine, D. Zakalik. Beaumont Hospital, 
Royal Oak, Michigan, U.S.A.
Objectives: Hereditary breast and ovarian cancer syndrome (h b o c s ) is 
associated with a mildly increased risk of cutaneous and ocular melanoma. Earlier 
studies have demonstrated ocular melanoma in association with BRCA2, but not 
BRCA1, mutations. We present a rare case of an ocular melanoma and primary 
peritoneal carcinoma in a BRCA1 mutation carrier.
Methods: a 62-year-old Caucasian female presented with an abnormal 
Papanicolaou smear and underwent a laparotomy, which revealed primary 
peritoneal carcinoma. Her past medical history was significant for decreased night 
vision, leading to the diagnosis of a left ocular melanoma (spindle-cell, type B) 
at age 57 years. She underwent a therapeutic enucleation at that time. Family 
history is remarkable for early-onset breast cancer in her sister and two nieces, all 
diagnosed in their 40s. The patient presented for genetic counselling and testing 
following the diagnosis of primary peritoneal carcinoma. The patient’s peripheral 
blood was sent for full sequence analysis of the BRCA1 and BRCA2 genes. direct 
d n a  sequence analysis was performed on the polymerase chain reaction products 
corresponding to the entire BRCA1 and BRCA2 coding region.
Results: The molecular analysis identified a deleterious mutation, 
2530delaG, in the BRCA1 gene. This is a frameshift mutation that results in 
premature truncation of the BRCA1 protein at amino acid position 808, confirming 
the diagnosis of h b o c s .
Conclusions: The patient described above developed two rare 
malignancies, ocular melanoma and primary peritoneal carcinoma. Earlier 
studies have identified a 2%–3% prevalence of BRCA2 mutations in younger 
individuals with ocular melanoma. This case represents the first report of an 
ocular melanoma in a BRCA1 carrier and highlights the unusual presentation of 
cancers in individuals with h b o c s .
Detection and Prevention of hereditary Breast Cancer
D. Farengo Clark,* S. Mento,† G. Grana.* *Cooper Cancer 
Institute, Voorhees, New Jersey, and †Arcadia University, Glenside, 
Pennsylvania, U.S.A.
There is a paucity of data looking at how breast cancers are diagnosed in 
BRCA carriers and the stage in which these women are diagnosed. Our hypothesis 
is that BRCA1/2 carriers will more often present with a palpable mass than be 
identified through imaging and that they will be diagnosed with advanced-stage 
disease that requires traditional chemotherapy. We also wanted to examine the 
relationship between mutation status and pathology. We conducted a retrospective 
evaluation of female breast cancer patients who carried BRCA1/2 mutations to 
determine how women find their cancers and how those cancers are treated. 
Our study included 66 women who were diagnosed with breast cancer and who 
carried a BRCA1/2 mutation. almost half the women presented with palpable 
masses, but only 1/2 were diagnosed by mammographic findings. Surprisingly, 
of the 66 cancers, 50 were diagnosed at stage 0–iib, and only 5 were diagnosed 
at stage iii or higher. BRCA1 cancers were more often triple-negative than were 
BRCA2 cancers (42% and 21% respectively). Although these cancers were 
diagnosed at early stages, 92% of BRCA1 carriers and 68% of BRCA2 carriers 
still were treated with traditional chemotherapy. We feel that, if a woman is 
presented with this data showing that an impending cancer will more often than 
not require chemotherapy, she may choose more aggressive management and opt 
for prophylactic mastectomy. Knowing that BRCA1 cancers are triple-negative 
may also change recommendations regarding the use of anti-hormonal agents 
and leave women with fewer prevention options. all of this information should 
be presented to women to help them make an informed decision about prevention 
when they receive results.
Risk Factors for Carcinoma of the Fallopian Tube in Women with 
a Germline BRCA Mutation and in Sporadic Cases
D. Vicus,*†d A. Finch,*d B. Rosen,† I. Fan,‡ L. Bradley,‡ I. Cass,§ P. 
Sun,* R. Royer,* B. Karlan,§ J. McLaughlin,‡ S.A. Narod,* on behalf 
of the Hereditary Ovarian Cancer Clinical Study Group. *Women’s 
College Hospital, †University Health Network, University of Toronto, 
and ‡Samuel Lunenfeld Research Institute, Toronto, Ontario, Canada; 
and §Cedars Sinai Medical Center, Los Angeles, California, U.S.A.
Objectives: To evaluate risk factors that may relate to the development of 
fallopian tube cancer in women with and without a BRCA mutation.
Methods: Subjects with fallopian tube cancer were identified from a large 
international registry of women that carry a BRCA1 or BRCA2 mutation (n = 
56) and from a population-based study of ovarian and fallopian tube cancer in 
Ontario, Canada (n = 67). BRCA mutation status was established for all subjects. 
all subjects completed a questionnaire about medical history and lifestyle factors. 
Subjects were matched with controls for date of birth within 4 years, for BRCA 
mutation (negative, BRCA1, BRCA2), country of residence, and past history of 
breast cancer (yes/no and matched within 5 years of diagnosis). Using conditional 
logistic regression, the odds ratio (o r ) and 95% confidence interval (c i ) were 
calculated for parity, body mass index, oral contraceptive use, tubal ligation, 
and hormone replacement therapy.
Results: We studied 105 women with fallopian tube cancer (48 with a BRCA1 
mutation, 10 with a BRCA2 mutation, and 47 with no identified BRCA mutation) 
and 958 matched controls. Increasing parity was associated with a decreased risk 
of fallopian tube cancer in non-carriers (trend per birth—o r : 0.65; 95% c i: 0.45 to 
0.93; p = 0.02), in BRCA1 carriers (o r : 0.78; 95% c i: 0.60 to 1.02; p = 0.07), and in 
BRCA2 carriers (o r : 0.44; 95% c i: 0.19 to 1.04; p = 0.06), but was significant only 
for non-carriers. Oral contraceptive use was protective for BRCA1 carriers (trend 
per year of use—o r : 0.90; 95% c i: 0.82 to 0.99; p = 0.03), but was not protective 
for non-carriers (o r : 0.99; 95% c i: 0.88 to 1.10; p = 0.80) or BRCA2 carriers (o r : 
0.95; 95% c i: 0.82 to 1.11; p = 0.53). No significant effects were observed for body 
mass index, hormone replacement therapy, or tubal ligation.
Conclusions: Parity and oral contraceptive use were associated with a 
decreased risk of fallopian tube cancer, but these effects were not observed 
consistently across all groups stratified by mutation. The risk factors for fallopian 
tube cancer appear to be similar to risk factors for ovarian cancer.
d  These authors contributed equally to this work.
BRCA Mutations, Risk and Outcome of Prostate Cancer
D. Gallagher, M. Gaudet, P. Pal, T. Kirchhoff, J. Bhatia, S. Fine,  
H. Scher, P. Scardino, L. Norton, M. Robson, K. Offit. Memorial  
Sloan–Kettering Cancer Center, New York, New York, U.S.A.
Objectives: To determine clinicopathologic characteristics of BRCA-
associated prostate cancer in men of Ashkenazi Jewish (a j ) ancestry.
Methods: We determined BRCA mutation prevalence in 832 a j  men with 
localized prostate cancer and 435 a j  controls, and compared age, stage, prostate-
specific antigen, Gleason score (g s ), overall survival, and other clinical outcome 
measures among 26 BRCA mutation carriers and 806 non-carriers. Kruskal–Wallis 
tests were used to compare age of diagnosis and g s , and logistic regression models 
were used to determine associations between carrier status, prostate cancer risk, 
and g s . Hazard ratios were estimated using Cox proportional hazards models.
Results: BRCA2 mutations were associated with tripled risk for prostate 
cancer [odds ratio (o r ): 3.18; 95% confidence interval (c i ): 1.52 to 6.66; p = 
0.002]. BRCA1 mutation conferred no increased risk. BRCA2 carriers presented 
at a younger age (median: 62 years vs. 68.2 years; p = 0.05). Adjusting for age, 
BRCA2 mutation carriers were more likely than non-carriers to have a Gleason 
score of 7 or higher [hazard ratio (h r ): 2.37; 95% c i : 1.14 to 4.94; p = 0.021], 
but BRCA1 mutation carriers were not (h r : 0.62; 95% c i : 0.12 to 3.10; p = 0.56). 
after 7254 person–years of follow-up, BRCA1 and BRCA2 mutation carriers, as 
compared with non-carriers, had an increased risk of developing biochemical 
recurrence (h r : 4.32; 95% c i : 1.31 to 13.62; p = 0.016 and h r : 2.41; 95% c i : 1.23 
to 4.75; p = 0.011 respectively) and castrate metastases (h r : 2.15; 95% c i : 0.28 
to 16.31; p = 0.46 and h r : 3.01; 95% c i : 1.26 to 7.14; p = 0.013). There was a 
greater risk of death from prostate cancer (h r : 5.16; 95% c i : 1.09 to 24.53; p = 
0.039 and h r : 5.48; 95% c i : 2.03 to 14.79; p = 0.001) for BRCA1 and BRCA2 
carriers respectively.
Conclusions: BRCA2 mutation carriers had an increased risk of prostate 
cancer, a younger age of onset, and a more aggressive phenotype. Prostate cancer 
cases with a BRCA1 or BRCA2 mutation were characterized by an adverse 
clinical outcome. These results may affect clinical management of this subset 
of hereditary prostate cancer.
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Single-Staged Breast Cancer Reconstruction Using the Combined 
Spectrum Expander/Implant
L. Lessard, L. Al-Salmi, A. Izadpanah. McGill University Health  
Centre, Montreal, Quebec, Canada.
Introduction: Breast reconstruction is an important procedure that requires 
attention to detail for optimal outcome. Spectrum implants (Mentor Corporation, 
Santa Barbara, CA, U.S.A.) have provided us with the tools to optimally adjust for 
achieving symmetry and patient satisfaction. Single-staged breast reconstruction 
with saline implants was first introduced by Becker in 1982. Despite advances 
in our surgical techniques and prosthesis, the reported complication rate remains 
high at 28%.
Purpose: We present the senior author’s experience over a period of 7 
years for immediate and delayed breast reconstruction as it relates to implant 
reconstruction. This is the first reported study of breast reconstruction using 
Spectrum Expander/Implant with the use of the same retropectoral technique 
and no alloderm. All implants were saline-filled.
Methods: a retrospective review analysis of patients undergoing Spectrum 
implants by the senior author from 2001 to 2008 is presented. Specific attention 
is paid to factors associated with major complications.
Results: a total of 44 patients underwent 67 Spectrum breast implant 
reconstructions. The mean age of the study patients was 42.7 years (standard 
deviation: ±11.6 years; range: 17–67 years). There was no skin necrosis (0%). 
Complications requiring reoperation and general anesthesia were capsular 
contracture (n = 10; 14.9%), periprosthetic infection (n = 3; 4.5%), and delayed 
sudden deflation (n = 2; 3.0%). Only 1 patient was subsequently judged not 
suitable for reoperation/reconstruction because of severe neutropenia. The 
subcutaneous valves were removed under local anesthesia during nipple 
reconstruction without any complication. Photographic technical tips and final 
results are presented.
Conclusions: Use of a versatile integrated all-in-one expander/
implant (Spectrum) can achieve great results with minimal complication and 
reoperation rates.
Early Experiences of the Calgary Breast health Program  
high-Risk Breast Cancer Clinic
S. Lupichuk,*† J. Ng,‡ K. Blaikie,† S. Leith,† T. Power,† B. Walley.*† 
*Tom Baker Cancer Centre and †Alberta Health Services–Calgary, 
Breast Health Program, Calgary, Alberta, Canada; and ‡Queen’s 
University, Kingston, Ontario, Canada.
Background: In 2007, funding was obtained to formalize and evaluate the 
Calgary Breast Health Program high-risk breast cancer clinic, which commenced 
February 2008. The team included a physician, nurse, psychologist, and clerical 
assistant. The target client population included individuals at high genetic risk 
(per medical genetics), women diagnosed with lobular carcinoma in situ or 
atypical hyperplasia, and women who received mantle radiotherapy in childhood 
or teenage years. The initial appointment involved self-completion of a needs 
assessment questionnaire, a brief meeting with the psychologist, breast (± ovarian) 
cancer risk assessment, overview of screening and risk-reduction options, and 
a nurse-led discussion of lifestyle strategies and signs or symptoms of breast 
(± ovarian) cancer. The pilot period was completed in March 2009, and the clinic 
continues to operate under the same model.
Objectives: To describe the demographic profile of clients; the perceived 
pre-consultation needs of clients; the recommendations made by the clinic; and 
the referrals generated.
Methods: all clients seen from February 2008 through May 2009 who 
agreed to be contacted regarding further research will be sent a consent package. 
Pertinent information on consenting clients will be abstracted from charts. 
descriptive statistics will be applied to the data obtained.
Results: By May 31, 2009, the clinic had received 116 referrals, and 73 
consultations had been completed. Referrals came from medical genetics (n = 
57), primary care (n = 38), surgery (n = 20), gynecology (n = 1), and psychology 
(n = 1). Of the referrals not seen, most were referred directly to medical genetics 
(n = 22) or are waiting on a pending appointment (n = 6). For consenting clients 
seen by the clinic, aggregate data describing demographic profile, perceived pre-
consultation needs, recommendations made, and referrals made are presented.
Conclusions: The introduction of a formal high-risk breast cancer clinic in 
Calgary has been a feasible undertaking. assessment and revision of the current 
clinic model is ongoing.
hereditary Breast/Ovarian Cancer high-Risk Clinic:  
Our First 12 Years
C. Kim–Sing, M. McCullum, J. Pike, K. Swenerton. BC Cancer Agency, 
Vancouver, British Columbia, Canada.
Objectives: To describe the clinic’s first 12 years of experience with high-
risk screening for women with confirmed BRCA1 or BRCA2 gene mutations.
Methods: To date, 262 women with BRCA1/2 mutations have seen a 
clinic physician and nurse specialist for consultation. Prophylactic mastectomy 
with reconstruction is an option discussed with all women, and high-risk breast 
screening is offered as the alternative. Screening includes clinical breast exam and 
imaging every 6 months, with an alternating schedule of breast m r i  (from age 25) 
and mammography (from age 30). Prophylactic bilateral salpingo-oophorectomy 
(p b s o) is recommended to all mutation carriers. Ovarian cancer screening is not 
currently recommended. Women are discharged to their family physician’s care 
after prophylactic surgeries, and those with a new cancer diagnosis or recurrence 
are referred to an oncologist.
Results: Of BRCA1/2 mutation carriers attending the clinic, 16% have 
had at least 1 new cancer diagnosis; 46 new cancers have been detected (26 in 
BRCA1-positive, 20 in BRCA2-positive), with 4 women having 2 new diagnoses. 
Cancers diagnosed include 24 invasive breast cancers, 7 ovarian cancers, 4 cases 
of ductal carcinoma in situ (d c i s ), 2 cases of lobular carcinoma in situ (l c i s ), 2 
fallopian tube (f t) cancers, 2 peritoneal cancers (both after p b s o), 2 pancreatic 
cancers, 1 malignant melanoma, 1 gastric cancer, and 1 colorectal cancer. Of the 
breast cancers, 10 were identified on m r i  screening. Six cancers were diagnosed 
by pathology review at the time of prophylactic surgery, including 3 ovarian 
cancers, 1 f t cancer, 1 breast cancer, and 1 l c i s , with an additional d c i s  diagnosis 
on contralateral mastectomy.
Conclusions: Over the past 12 years, the clinic has provided a valuable 
service to high-risk women in our province. Experienced clinicians offer 
information, support, referral to expert surgeons, breast imaging, and clinical 
follow-up. This high-risk clinic will provide ongoing opportunities to evaluate 
the efficacy of specific cancer risk management strategies.
Somatic Complaints in Women with Risk-Reducing Salpingo- 
Oophorectomy to Prevent hereditary Breast/Ovarian Cancer
T.M. Michelsen,*†‡ A.A. Dahl,‡§ C.G. Tropé,‡|| A. Dørum.‡|| *Department 
of Gynecology, Sørlandet Hospital Arendal, Arendal; †Rikshospitalet, 
Oslo University Hospital; and ‡Faculty Division, §Department of 
Clinical Cancer Research, and ||Section of Gynecological Oncology, The 
Norwegian Radium Hospital, Oslo, Norway.
Background: Risk-reducing salpingo-oophorectomy (r r s o ) is effective for 
preventing ovarian cancer in women from hereditary breast/ovarian cancer families, 
but the procedure may be associated with somatic morbidity and complaints. In 
this cross-sectional study, we aimed to study self-reported somatic complaints in 
women who had undergone r r s o .
Methods: Based on surgical records, we identified and invited 503 women 
who had undergone r r s o  after genetic counselling at a median of 6 years earlier. 
Among these, 338 (67%) completed questionnaires on demographic and medical 
issues, somatic complaints, and mental distress. We randomly allocated 5 age-
matched controls per case (n = 1690) among participants with intact ovaries from 
the population-based Norwegian Nord-Trøndelag Health Study.
Results: The r r s o  group had significantly more palpitations (p = 0.02), 
constipation (p = 0.01), pain and stiffness (p = 0.02), musculoskeletal disease (p = 
0.01), and osteoporosis (p = 0.02) than did the control group. In a multivariate analyses 
of the total sample, membership in the r r s o group was significantly associated 
with osteoporosis [odds ratio (o r ): 2.4; 95% confidence interval (c i): 1.3 to 4.5], 
musculoskeletal disease (o r : 1.7; 95% c i : 1.0 to 2.7), osteoarthritis (o r : 2.4; 95% c i : 1.7 to 
3.5), and constipation (o r : 1.4; 95% c i : 1.1 to 2.0). Current use of hormonal replacement 
therapy (h r t ) was significantly associated with musculoskeletal disease (o r : 1.5; 95% 
c i : 1.0 to 2.3), osteoporosis (o r : 2.0; 95% c i : 1.2 to 3.3), pain and stiffness (o r : 1.4; 
95% c i : 1.1 to 1.8), fibromyalgia (o r : 1.6; 95% c i : 1.1 to 2.5), nausea (o r : 1.5; 95% c i : 
1.1 to 2.1) and constipation (o r : 1.5; 95% c i : 1.2 to 1.9). In multivariate analyses of the 
r r s o  group only, no significant association was observed between the use of h r t  and 
somatic complaints, but time since r r s o  was significantly associated with osteoporosis 
(o r : 1.2; 95% c i : 1.1 to 1.3), nausea (o r : 0.9; 95% c i : 0.8 to 1.0), and constipation (o r : 
0.9; 95% c i : 0.9 to 1.0).
Conclusions: The r r s o group had more palpitations, constipation, and 
musculoskeletal disease than did the control group. Use of h r t  was associated with 
musculoskeletal pain conditions and gastrointestinal symptoms, which may indicate 
that women with more symptoms choose h r t . Follow-up examinations after r r s o  
should also focus on somatic complaints.
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Effect of Reminder Telephone Calls on Mammography  
Compliance in high-Risk Women
C. Snyder, H. Lynch. Creighton University, Omaha, Nebraska, U.S.A.
The effect of a reminder telephone call intervention designed to encourage 
mammography has not been systematically studied in a high-risk population in 
which compliance is crucial. We hypothesize that a simple reminder telephone 
call would significantly increase mammography uptake in high-risk women as 
compared with a control group. In 447 high-risk women, consent to participate 
in the study was obtained. Interestingly, 346 (77%) of these women self-reported 
being compliant in obtaining annual mammography for the preceding 2 years. 
Verification was established in a subset of these women by obtaining their mam-
mogram reports. Subjects who were noncompliant by self-report (n = 32) were 
randomized to the intervention or the control group. reminder and follow-up 
telephone calls were completed on 16 women in the experimental group, and 
follow-up calls were completed on 15 women in the control group. One woman 
was excluded from the study after being diagnosed with breast cancer upon obtain-
ing a mammogram. A statistical difference (p = 0.0017) was observed between 
the two groups in support of the hypothesis that mammography compliance in 
high-risk women can be increased if an intervention such as a simple reminder 
call is implemented. Future studies should identify barriers in obtaining mam-
mograms in these high-risk individuals.
Outcomes and Uptake of Risk-Reducing Salpingo-Oophorectomy 
in Women Over the Age of 40 Years at high Familial Risk of 
Ovarian Cancer
R. Manchanda,* A. Abdelraheem,† M. Johnson,* M. Brunell,* A. 
Rosenthal,* S. Gessler,* C. Brunell,§ E. Benjamin,‡ D. Oram,† I. 
Jacobs,*e U. Menon.*e *Gynaecological Oncology, Institute for 
Women’s Health, University College London; †Barts and the London 
Hospital; and Departments of ‡Pathology and §Radiology, University 
College London Hospital, London, U.K.
Objectives: To evaluate outcomes and factors affecting uptake of risk-
reducing salpingo-oophorectomy (r r s o ) in women at high risk for ovarian cancer 
over the age of 40 years.
Methods: Prospectively collected data of women attending a Familial 
Cancer Clinic between 2004 and 2009 were analyzed. The preferred management 
option recommended to women over the age of 40 years with a 10% or greater 
estimated lifetime risk of ovarian cancer was r r s o  with peritoneal washings. 
Those declining surgery opted for screening under the United Kingdom Familial 
Ovarian Cancer Screening Study. a strict histopathologic protocol with serial 
slicing was used for r r s o  specimens.
Results: Of 1518 high-risk women from breast/ovarian cancer families 
seen from 2004 to 2009, 517 were below 40 years of age. Of the 1001 others, 
181 were BRCA1/2 carriers, and 820 had unknown mutation status (u m s ). Of the 
1001 women, 263 (of whom 33.5% were carriers) chose r r s o, and 738 (of whom 
12.6% were carriers) preferred screening.
The median ages (and interquartile ranges) for the r r s o  and screening 
groups were 50.9 (45.3, 57) years and 47.5 (43.2, 54.9) years respectively (p = 
0.001). Women undergoing r r s o  were more likely to have had breast cancer 
(p < 0.0005), to have a relative below the age of 50 years with ovarian cancer 
(p = 0.012), to have a parity of P2 or greater (p = 0.039), to be postmenopausal 
(p < 0.0005), and to carry BRCA gene mutations (p < 0.0005). The median age 
of women undergoing r r s o  was lower in BRCA carriers than in u m s  women 
(p < 0.000001).
The occult cancer rate in the whole cohort was 3.8% [95% confidence 
interval (c i ): 1.84% to 6.88%]. Of the 7 tubal and 3 primary ovarian cancers, 6 
were in mutation carriers, for a 6.8% incidence (95% c i : 2.5% to 14.25%), and 4 
were in u m s  women for a 2.3% incidence (95% c i : 0.63% to 5.75%; p = 0.09).
Conclusions: Various factors affect decision-making in high-risk women. 
BRCA carriers and u m s  women both have a high occult malignancy rate, and the 
age at detection of lesions is similar in both groups. It is important that women 
are made aware of these facts, because u m s  women tend to delay surgery till 
becoming postmenopausal.
e  Equal contribution.
Results of a Phase II Open-Label Nonrandomized Trial of 
Cisplatin Chemotherapy in Patients with BRCA1-Positive 
Metastatic Breast Cancer
T. Byrski,* R. Dent,† D. Zuziak,‡ M. Foszczyńska–Kłoda,§ J. 
Gronwald,* T. Huzarski,* C. Cybulski,* J. Lubiński,* S.A. Narod.|| 
*Department of Genetics and Pathology, International Hereditary 
Cancer Center, Pomeranian Medical University, Szczecin, Poland; 
†Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, 
Ontario, Canada; ‡Regional Oncology Hospital, Bielsko Biała, 
and §Regional Oncology Hospital, Szczecin, Poland; and ||Women’s 
College Research Institute, University of Toronto, Toronto, Ontario, 
Canada.
Purpose: To evaluate the efficacy of cisplatin chemotherapy in BRCA1 
mutation carriers with metastatic breast cancer.
Design: In a phase ii open-label study, 20 patients with metastatic breast 
cancer who carried a mutation in BRCA1 were treated with cisplatin 75 mg/m2 
intravenously every 3 weeks as part of a 21-day cycle for 6 cycles. restaging 
studies to assess response were performed after cycles 2 and 6, and every 
3 months thereafter.
Results: Between July 2007 and January 2009, 20 patients were enrolled. 
at baseline, 65% had received prior adjuvant chemotherapy, and 55%, prior 
chemotherapy for metastatic breast cancer. Mean age in the group was 48 
years (range: 32–70 years); 30% were estrogen (e r) or progesterone receptor 
(p r)–positive; 70% were e r/p r/h e r 2–negative; and 0% were h e r 2-positive. Overall 
response rate was 80%; 9 patients experienced a complete clinical response 
(45%), and 7 experienced a partial response (35%). The 1-year survival was 
93%. Cisplatin-related adverse events, including nausea (50%), anemia (5%), 
and neutropenia (35%), were mostly mild to moderate in severity. One patient 
discontinued therapy because of grade 4 neutropenia.
Conclusions: This phase ii study demonstrates that cisplatin chemotherapy 
has high activity in women with a BRCA1 mutation and metastatic breast cancer 
and is generally well tolerated.
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Increasing Medical Student Awareness of Inherited Susceptibility 
to Breast Cancer
J.S.A. Wronzberg,* S.M. Nikkel,*† E.M. Tomiak.*†‡ *Faculty of 
Medicine, University of Ottawa; †Department of Genetics, Children’s 
Hospital of Eastern Ontario; and ‡Women’s Breast Health Centre, The 
Ottawa Hospital, Ottawa, Ontario, Canada.
In 2007, it was reported that North american medical school curricula 
are lacking in the area of clinical genetics (Thurston VC et al. Acad Med 
2007;82:441–5). Implementation of an online self-directed learning module 
(s l m) provides students with an interactive case-based approach that simulates 
real-world uses of genetic testing and highlights the implications of such tests 
on patient decision-making.
Objectives: To design and implement a s l m for medical students to improve 
their knowledge of hereditary cancers using breast cancer as the model.
Methods: The s l m will be designed by a medical student working together 
with a clinical geneticist and a medical oncologist. The objectives for the module 
are focused on providing students with knowledge in three areas:
•    How to interpret a patient’s personal and family history to assess level 
of risk
•    Understanding the implications of genetic testing as they relate to 
hereditary cancers
•    Increasing awareness of the diversity of psychosocial issues facing 
women and their families who are found to have a BRCA mutation
Results: Assessment of the efficacy of this s l m as a teaching tool will be 
carried out using a focus group of medical students. The focus group will examine 
the effectiveness of the s l m in increasing student knowledge and in addressing the 
limitations of the modality so that those limitations can be overcome.
Conclusions: s l ms present an excellent opportunity to provide early 
impact in medical school curricula. By integrating knowledge from several key 
disciplines (genetics, oncology, and gynecology) with appropriate emphasis 
on the psychosocial aspects of risk assignment, medical students will have an 
increased understanding of adult-onset genetic conditions.
Personal Genetics and Cancer Prevention: Mapping Public 
Representations and Psychosocial Response to Testing
C. Ouellette, R. Hyde–Lay, T. Caulfield. Health Law Institute, Law 
Centre, University of Alberta, Edmonton, Alberta, Canada.
It has been suggested that the age of personal genetics is here (Hudson, 
2009; Walsh, 2009). Indeed, a service offered by the personal genetics company, 
23andMe, was named invention of the year for 2008 (Hamilton, 2008). And in 
the same year, the investigation of genetic variation was deemed the scientific 
breakthrough of the year by Science magazine. The entire field also gets a 
tremendous amount of media attention, garnering almost daily coverage in the 
popular press.
One of the foundational rationales for this emerging field—and the reason 
for much of the excitement–is that it will allow for a more holistic and preventive 
approach to the management of chronic diseases, including many forms of cancer 
(Scheuner et al., 2008). This rationale can be found in both the academic literature 
and in the marketing strategies of companies offering direct-to-consumer genetic 
tests. However, current research regarding psychosocial response to genetic 
testing is mixed, clouding the preventive rationale for the field.
Our study contrasts public representations of risks and benefits with 
behaviour research. Firstly, we map the psychosocial risks and benefits associated 
with the emerging field of personal genetics, as communicated through public 
representations. Secondly, we critically assess the public representation of 
personal genetics in relation to literature on cancer prevention strategies and its 
role as a means of health communication. In response to personal genetic testing, 
how are cancer prevention strategies framed? do the representations support a 
preventive approach to personal genetics? How might public representations be 
improved to promote preventive behaviour in response to testing? Our study 
hopes to provide insight into the current state of public communications and 
psychosocial response to genetic testing.
Secondary Use of Data and Samples from Deceased Participants: 
What Are the Legal and Ethical Constraints?
K. Bédard,* E. Lévesque,† D. Avard,† J. Simard.‡ *Université de 
Montréal and †Centre of Genomics and Policy, McGill University, 
Montreal; and ‡Faculté de médecine, Université Laval, Quebec City, 
Quebec, Canada.
Context: Biologic samples and data used in research may, in some 
cases, be of great use for another research project. This is called “secondary 
use.” The secondary use of data and samples is current practice among health 
care researchers, even more so since the increasing use of biobanks. However, 
particular issues arise when the participant to whom the samples and data are 
linked is deceased. although ethical and legal framing of secondary use of 
samples and data of live participants is in place and is consistent across various 
normative texts, the framework concerning deceased participants is often less 
developed and sometimes inexistent. although the value of these samples is often 
inestimable, using them may sometimes prove to be complex.
Methods: Our research consists of an analysis of the legal and ethical 
framework in place in Quebec and Canada concerning the secondary use of data 
and samples from deceased individuals. We analyzed how the various norms 
address some specific questions such as the scope of consent for use after death 
and considerations concerning the wishes of living relatives related to the use 
of data and samples of a deceased individual, when there is no prior indication 
of individual choice.
Results: We will provide a synthesis of the elements that need to be taken 
into account before considering the secondary use of such material. We will 
examine, by way of example, the procedure set in place to allow secondary use 
in the case of the continuation of the i n h e r i t  breast cancer project, funded by the 
Canadian Institutes of Health research Team in Familial risks of Breast Cancer. 
Finally, we will conclude by presenting lessons learned, which could be helpful 
for the elaboration of a uniform ethical and legal framework in Canada.
Breast Cancer at Less Than 36 Years of Age Is a Strong Predicator 
of BRCA1/2 Status in French-Canadian Cancer Families
L. Cavallone,* S.L. Arcand,† C.M. Maugard,‡§ A.M. Mes–Masson,§|| P. 
Ghadirian,# D. Provencher,||** P.N. Tonin.*†‡‡ *Department of Human 
Genetics, McGill University; †The Research Institute of the McGill 
University Health Centre; ‡Centre Hospitalier de l’Université de Montréal 
(C h u m ); §Département de médecine, Université de Montréal; ||Centre de 
Recherche du C h u m , Institut du Cancer de Montréal; #Epidemiology Research 
Unit, Research Centre, C h u m –Hôtel-Dieu; **Département d’obstétrique 
gynécologie, Université de Montréal; and ‡‡Department of Medicine, McGill 
University, Montreal, Quebec, Canada.
The presence of a breast cancer case diagnosed before 36 years of age is a strong 
indicator for the presence of a BRCA1/2 mutation in French-Canadian (f c) hereditary 
breast and/or ovarian cancer (h b c /h b o c ) families. Earlier studies were limited by 
screening for the mutations that recur in this founder population. We have assessed the 
contribution of BRCA1/2 to 75 h b c  and 51 h b o c  f c families who have at least 3 cancer 
cases per family and who have undergone Myriad Genetics mutation screening and 
multiplex ligation-dependent probe amplification analysis for rearrangements. About 
50% of the h b c  families were mutation-negative. about 32% were 3-case families, in 
which 71% were mutation-negative (p = 0.014). The distribution of cases relative to an 
index tested case in the h b c  mutation-negative group differed from that in the mutation-
positive group (p = 0.004), where more first-degree relatives with breast cancer were 
observed in the mutation-negative families (56%) than in the mutation-positive families 
(35%, p = 0.0009). The frequency of breast cancer diagnosed before the age of 36 
years in the h b c  mutation-negative families (6%) differed significantly from that in 
the BRCA1 (23%, p = 0.0002) and BRCA2 (23%, p < 1x105) mutation-positive h b c  
families. Thus, although 50% of the h b c  families harboured a mutation, about 80% of 
families with at least 1 breast cancer case diagnosed below the age of 36 years were 
mutation-positive. about 69% of the h b o c  families were mutation-positive, and as 
compared with the 19% of mutation-negative families, 54% of those mutation-positive 
families contained at least 1 breast cancer case diagnosed below the age of 36 years 
(p = 0.017). Of the 18 h b o c  families with fewer than 3 cases of breast cancer, half of 
the 10 mutation-positive families contained at least 1 breast cancer case diagnosed 
below the age of 36 years as compared with no cases diagnosed in mutation-negative 
h b o c  families in this sub-group. These observations reaffirm the significance of the 
presence of very young age of diagnosis of breast cancer with h b c  and h b o c  families 
and should facilitate decisions aimed at genetic testing for BRCA mutations.
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THIrd INTErNaTIONal SYMPOSIUM ON HBOC
Transitional-Cell Ovarian Carcinoma Is Associated with Germline 
BRCA1/2 Mutations
L.M. Chen, J.T. Rabban, B. Crawford, J. Hwang, J.K. Chan, C.B. 
Powell. UCSF Helen Diller Family Comprehensive Cancer Center, 
San Francisco, California, U.S.A.
Objectives: The population prevalence of BRCA1 and BRCA2 mutations for 
women with epithelial ovarian carcinoma is estimated to be around 11%–15%, 
with the predominant histology of tumours being serous. Our study is designed 
to estimate the strength of the association between transitional-cell ovarian 
carcinomas and germline mutations in BRCA1 and BRCA2.
Methods: We searched our pathology department’s database for cases of 
epithelial ovarian carcinoma with transitional-cell histology. Patients (or their 
surviving first-degree relatives) were offered genetic counselling and testing for 
germline mutations in BRCA1 and BRCA2. Pathology slides were reviewed and 
confirmed by a gynecologic pathologist.
Results: Between 1996 and 2008, 25 patients with a mean age of 58 
years (range: 39–75 years) were identified. Ten patients and one patient’s son 
underwent genetic testing. The other patients could not be tested because they 
were either deceased or lost to follow-up. We identified 6 BRCA1 and 2 BRCA2 
mutation carriers with a mean age of 57 years (range: 51–63 years). A conservative 
estimate of the prevalence of BRCA1 and BRCA2 mutations, including all 25 
transitional-cell histology patients as the denominator, identified a frequency 
of 32% (95% confidence interval: 14%–50%). If we had been able to offer 
testing to all patients in our transitional-cell cohort, the prevalence of BRCA1/2 
mutations may have been even greater. all patients who tested positive had a 
family history of cancer, including 5 families with breast cancer, 3 with ovarian 
cancer, and 2 with colon cancer.
Conclusions: Transitional-cell histology apparently has a higher prevalence 
of BRCA1/2 mutation carriers than is found in the general population. Further 
molecular characterization may elucidate whether the transitional-cell and serous 
histologies represent distinct phenotypes.
Long-Term Stability of Knowledge Acquired During Genetic 
Counselling for Breast/Ovarian Cancer Susceptibility
M. Dorval,*† K. Bouchard,† C. Côté,† S. Camden,† J. Simard.*† 
*Faculty of Pharmacy, Laval University; †URESP, Centre de recherche 
du C h a ; ‡Faculty of Medicine, Laval University; and §Laboratoire de 
génomique des cancers, Centre de recherche CHUL, Quebec City, 
Quebec, Canada.
Purpose: Studies have shown that standard genetic counselling increases 
knowledge of breast and ovarian cancer genetics. However, little is known about 
the retention of such information long after test result disclosure. This study 
assesses the stability of knowledge acquired during pre-test genetic counselling 
up to 3 years following BRCA1/2 test result disclosure.
Methods: Participants were a consecutive series of 429 French-Canadian 
women (89 carriers, 120 non-carriers, and 220 with an inconclusive test result) 
from 187 families, who were tested for BRCA1/2 mutations as part of the i n h e r i t  
b r c a s multidisciplinary research program. Knowledge about BRCA1/2 testing 
was assessed by a 19-item true–false measure at the pre-test genetic counselling 
session and 3 years after result disclosure. Knowledge scores are expressed as 
percentages of correct answers.
Results: Three years post-disclosure, mean knowledge scores were 
moderate (56.7 ± 18.2) and lower than those at pre-test genetic counselling 
[58.9 ± 18.7; paired t-test p = 0.0059 (intra-class correlation coefficient: 0.58)]. 
an average of 70% of participants who answered correctly to a given item 
at pre-test also answered correctly at 3 years. In multivariate models, higher 
education (p = 0.02) and older age (p = 0.04) were associated with a lower 
retention of information acquired during pre-test genetic counselling. However, 
women’s retention of information was not affected by test result, cancer status, 
psychological distress, or elapsed time between pre- and post-measurements.
Conclusions: although knowledge acquired during a standard BRCA1/2 
genetic counselling session could be improved, information correctly learned was 
remembered for an extended period of time by most participants.
A Study of Preventive Practices Among Canadian Women with a 
BRCA1 or BRCA2 Genetic Mutation
M. Enmore,* C. Kim–Sing,† S. Armel,‡ L. Bordeleau,§|| D. Gilchrist,# 
E. Warner,** A. Chudley,†† E. Lemire,‡‡ P. Ghadirian,§§ S. Narod,* K. 
Metcalfe.* *Women’s College Research Institute, Toronto, Ontario; 
†BC Cancer Agency, Vancouver, British Columbia; ‡Princess Margaret 
Hospital, Toronto, Ontario; §Juravinski Cancer Centre, Hamilton, 
Ontario; ||Mount Sinai Hospital, Toronto, Ontario; #University of 
Alberta Hospital, Edmonton, Alberta; **Sunnybrook Health Sciences 
Centre, Toronto, Ontario; ††Children’s Hospital, Winnipeg, Manitoba; 
‡‡Royal University Hospital, Saskatoon, Saskatchewan; §§Hotel-Dieu 
(CHUM), Montreal, Quebec, Canada.
Background: Women with a BRCA1 or BRCA2 mutation may elect not to 
undergo preventive treatment options despite their availability. In this study, we 
examined Canadian women’s preventive practices and the reasons that high-risk 
women elect not to adopt cancer preventive options.
Methods: Eligible patients were identified from a database of BRCA1 and 
BRCA2 mutation carriers. A study-specific questionnaire was mailed to each 
eligible woman. The questions focused on uptake of prophylactic mastectomy, 
prophylactic oophorectomy, chemoprevention, and screening. reasons for not 
electing an option were also examined.
Results: Of the 625 eligible women contacted, 464 (74%) women returned 
completed questionnaires, 12 (2.6%) of whom underwent no preventive options. 
The women’s mean age was 51.6 years (range: 25–70 years), and they received 
their genetic test results a mean of 79.2 months (range: 18–239 months) before 
completing the questionnaire. Of the 218 women without breast cancer, 147 
(67%) opted against prophylactic mastectomy, because of body image and 
sexuality concerns, and a preference for other preventive options; 49 (22%) 
opted against prophylactic oophorectomy because of concerns about medical 
side effects, menopausal symptoms, and effects on sexuality; 195 (89%) opted 
against preventive tamoxifen because of concerns about side effects and lack of 
recommendation; and 49 (22%) opted against preventive magnetic resonance 
imaging because of lack of access, availability, and recommendation.
Conclusions: Health care providers should ensure that women with a 
BRCA1 or BRCA2 mutation are presented with all preventive options, should be 
more proactive in addressing the concerns of these women, and should encourage 
informed decision-making about suitable preventive options.
Efficiency	of	BRCAPRO	and	Myriad	Models	and	the	Use	of	 
Mutation Probability Thresholds for BRCA1/2 Mutation  
Detection: A Retrospective Evaluation
E.B. Gomez Garcia,*† J.J.T. van Harssel,* Y. Detisch,* R.D. Brandao,*† 
A.D.C. Paulussen,* M.J. Blok,* C.E.P. van Roozendaal.* *Clinical Genetics, 
University Hospital Maastricht, and †Research Institute Growth and Devel-
opment (GROW), University of Maastricht, Maastricht, Netherlands.
Considerable differences exist between countries in the mutation prob-
ability methods and thresholds used to select patients for BRCA1 and BRCA2 
genetic testing.
Objectives: To assess the efficiency of the mutation probability methods 
b r c a p r o  and Myriad, as compared with criteria based on cancer history in the 
family, to select patients eligible for BRCA1/2 mutation detection.
Methods: We retrospectively calculated the b r c a p r o  and Myriad prob-
abilities in 307 probands who had previously been selected for d n a  analysis 
according to a list of eligibility criteria based on number of first- and second-
degree relatives affected with breast cancer (b c ) and/or ovarian cancer (o c ), age 
of diagnosis, presence of bilateral b c , and b c  in men. Until the year 2000, d n a  
analysis was performed using the protein truncation test (p t t). The d n a  from 
patients in whom no mutation was initially found using the p t t later on underwent 
complete genetic screening.
Results: The p t t detected 21 mutations (6.5%); complete genetic screen-
ing identified an additional 32 mutations (10.4%) and 11 unclassified variants 
(u v s—3.6%). Compared with cancer history, a threshold of 10% with b r c a p r o or 
with Myriad excluded about 40% of the patients from analysis, including 4 patients 
with a mutation and probabilities under 10% with both programs. all 4 probands had 
a BRCA2 mutation. The b r c a p r o  and Myriad methods showed similar specificity at 
10% threshold, and overall, b r c a p r o  was more sensitive than Myriad. Only 2 of the 
probands with a u v  had probabilities above 20% with b r c a p r o and Myriad.
Conclusions: The mutation probability models b r c a p r o  and Myriad are 
economically more efficient than are cancer history criteria alone. For the de-
tection of BRCA1 mutations, b r c a p r o , at a 10% threshold, is equally sensitive; 
however, for BRCA2 mutations, cancer history is the most sensitive. Most of the 
patients with a u v  have low probabilities with both methods, which may be an 
indicator of the lack of pathogenicity of those u v s.
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Is It Time for Population Genetic Testing for BRCA1 and BRCA2 
in the Jewish Population?
K. Metcalfe,*† A. Poll,† R. Royer,† M. Llacuachaqui,† A. Tulman,† 
P. Sun,† S. Narod.† *University of Toronto and †Women’s College 
Research Institute, Toronto, Ontario, Canada.
Introduction: There are 2 founder mutations in BRCA1 and 1 founder 
mutation in BRCA2 that are present in up to 2.5% of ashkenazi Jewish women. 
To date, it has not been proposed that the entire female Jewish population be 
eligible for screening. However, given the high frequency of mutations in the 
Jewish population at large, a full-population approach may be rational. Current 
guidelines for genetic testing in Ontario, Canada, stipulate the family history 
of cancer that must be present to confer eligibility for testing. little is known 
about the appropriateness of these guidelines in the Jewish population and the 
acceptance of genetic testing in this group of women.
Methods: Eligible subjects were women who self-identified as (Ashkenazi 
or Sephardic) Jewish, who were between the ages of 25 and 80 years, and who 
resided in Ontario. Study subjects were recruited through a description of the 
study that was published in a national newspaper on a single occasion in May 
2008. Women were asked to complete a study questionnaire and a family history 
questionnaire, and to provide a blood or saliva sample. risks of mutation were 
estimated for each woman using ibis software.
Results: The overall mutation prevalence in the 2080 women who enrolled 
in the study was 1.1% (0.5% in BRCA1 and 0.6% in BRCA2). Of the 22 families, 
10 (45%) would have met the criteria for genetic testing for BRCA1 and BRCA2 
under current guidelines from the Ontario Ministry of Health and long-Term 
Care. There were no differences in risk of mutation for those with and without 
a BRCA1 or BRCA2 mutation (3.9% vs. 1.2%, p = 0.23). However, estimates 
of mutation risk for women with a BRCA1 mutation were higher than for those 
without a mutation (7.6% vs. 1.2%; p ≤ 10–4). This was not observed for women 
with a BRCA2 mutation compared with those with no BRCA mutation (0.8% 
vs. 1.2%; p = 0.32).
Conclusions: The prevalence of BRCA mutations in unselected Jewish 
women from Ontario, Canada, was lower than previously reported. However, 
many of the women would not have met the criteria for testing based on family 
history of cancer. Population screening for BRCA mutations should be considered 
for the Jewish population.
Recruitment of a Population-Based Sample of Black Women  
for a Study of Inherited Breast Cancer Using a  
Cancer Registry–Based Approach
T. Pal, S. Vadaparampil. Moffitt Cancer Center, Tampa, Florida, U.S.A.
Objectives: We investigated BRCA1 and BRCA2 (BRCA) mutations in a 
population-based sample of black women diagnosed with breast cancer below the 
age of 50 years, because of the disproportionate numbers affected with early-onset 
breast cancer. Furthermore, because black people are typically underrepresented 
in genetic research studies, we sought to understand the factors associated with 
recruitment activities and study participation.
Methods: Following intuitional research board approvals, the State 
Cancer registry released demographic, clinical, and contact information on all 
eligible participants. State-mandated recruitment methods included 2 mailings, 3 
weeks apart, with a telephone response card for patients who did not wish to be 
contacted by telephone. If no patient response was received within 3 weeks of the 
second mailing, a member of the study team contacted the patient by telephone. 
Participation involved a genetic counselling session over the telephone, and 
collection of blood or saliva for BRCA testing.
Results: Of the 209 eligible patients identified by the cancer registry, 
contact was established with 87, of whom 82 were eligible for study participation. 
The overall rate of interest in study participation was 80% (including 93% 
for passive follow-up and 68% for active follow-up), of whom 48 have been 
consented to date. There were no differences in the clinical and demographic 
characteristics of participants and nonparticipants.
Conclusions: This is the first study conducted through a State Cancer 
registry in which the primary goal was to recruit participants for genetic 
counselling and testing for inherited breast cancer. Use of active follow-up 
methods was important in study recruitment. In contrast with many earlier 
studies, our results suggest that black women with early-onset breast cancer are 
interested in participating in studies of genetics and breast cancer, indicating that 
participation rates in black women may be enhanced by carefully considering 
methods to facilitate participation.
Critical Evaluation of BRCA1/2 Mutation Detection Rates in 
Southwestern Ontario
K. Panabaker, N. Scanlan, T. Paling, P. Ainsworth, J. Jung. London 
Health Sciences Centre, London, Ontario, Canada.
deleterious mutations in the BRCA1/2 genes have not been identified in 
high-risk families as often as originally expected. In clinical practice, predictions 
of BRCA1/2 mutation probability are sometimes made using various statistical 
models. When such models are applied to the same person, a wide range of 
probabilities is revealed. although trying to provide best practice to patients, 
economic challenges also exist in the health care environment. For these reasons, 
the Cancer Genetics team at the london Health Sciences Centre critically 
evaluated our experiences regarding cancer risk assessment and our associated 
BRCA1/2 mutation detection rate. In Ontario in 2000, a provincial committee 
established 13 eligibility criteria for hereditary breast/ovarian cancer (h b o c ) 
screening based on the medical literature at that time, offering gene analysis 
to individuals with a perceived 10% or greater risk of having a BRCA1/2 gene 
mutation. The methodology of this study included a review of all pedigrees, 
of eligibility criteria, and of genetic test results of individuals (n = 1270) who 
participated in index BRCA1/2 testing from 2000 to 2008. a consistent approach 
to determining which eligibility criteria were used in each case was pertinent 
to the analysis. The results revealed that one of the criteria (3 or more cases 
of breast and/or ovarian cancer, any age), representing 48% (608/1270) of all 
individuals tested, reported a 12.3% (75/608) overall mutation detection rate. 
However, a subset of this group (3 or more cases of breast cancer, age over 50 
years), representing 31% (189/608) of this category, showed only a 2.6% (5/189) 
positivity rate. Using a conservatively priced h b o c  screen ($1500), it takes 
approximately $56,000 to detect 1 mutation-positive individual in this subset. 
This finding could represent a significant cost savings to the current service 
testing program in Ontario. Our next goal is to determine if other cancer genetics 
programs in Ontario experience similar results in their own region, to provide 
further evidence to influence provincial decision-making.
We Are On the Manchester Bandwagon—So how Are We Doing?
N. Poplawski,*†‡ J. Armstrong,‡ K. Ryan,‡ G. Suthers.†‡ *Women’s 
and Children’s Hospital, North Adelaide; †University of Adelaide, 
Adelaide; and ‡SA Pathology WCH Site, North Adelaide, South 
Australia, Australia.
Background: The american Society of Clinical Oncology recommends 
offering BRCA1/2 mutation searching to cancer-affected individuals when 
the probability of identifying a mutation is 10% or higher (J Clin Oncol 
1996;14:1730–6). In September 2007, our unit began prospectively triaging 
familial breast and/or ovarian cancer families for BRCA1/2 genetic testing using 
a combined Manchester score (combined-MS—J Med Genet 2004;41:474–80; 
J Med Genet 2005;42:e39). This method was chosen because of its simplicity; 
the score can be calculated manually without the need for a computer, and the 
score can be easily recalculated in an outpatient setting after clarification of a 
family history.
Objectives: To retrospectively audit our unit’s BRCA1/2 mutation detection 
rate, based on the combined-MS.
Patients and Methods: Between early 1995 and april 30, 2009, our 
service initiated BRCA1 and BRCA2 genetic testing in 939 breast and/or ovarian 
cancer–affected probands. Using in-house clinical criteria, 827 of the 939 had 
initially been triaged to BRCA1/2 testing, and a retrospective combined-MS was 
calculated for these probands; 112 had been triaged to testing using a prospectively 
calculated combined-MS.
Results: Pathogenic BRCA1/2 mutations were detected in 152 of 939 
probands tested (16.1%). When the combined-MS was considered, pathogenic 
BRCA1/2 mutations were detected in almost one quarter of probands with a 
combined-MS above 15 (136/566, 24.0%), but in less than 5% of probands with 
a combined-MS of 15 or lower (16/373, 4.3%). The probability of detecting a 
pathogenic mutation increased as the combined-MS increased, with the 10% 
mutation detection threshold reached at a combined-MS of 16 (based on a best-fit 
trend line, where R2 = 0.92).
Conclusions: Our experience suggests that it is appropriate to triage 
familial breast and/or ovarian cancer families to BRCA1/2 genetic testing when 
the combined Manchester score is more than 15.
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Non-Acceptance of an Appointment at the Familial Cancer Clinic: 
A Preliminary Telephone Survey
N. Poplawski,*†‡ K. Ryan,† J. Armstrong,† M. Raciti,† S. Russell,† 
G. Suthers†‡ D. Trott.† *Women’s and Children’s Hospital and †SA 
Pathology WCH Site, North Adelaide, and ‡University of Adelaide, 
Adelaide, South Australia, Australia.
Purpose and Methods: a telephone survey was used to determine why 
some referred clients do not complete and return pre-clinic forms (p c f s—includes 
family history form, personal medical record consent, individual medical history 
form, and clinic location preference form), despite being informed that an 
appointment will be arranged only after the p c f s are returned.
Results: a group of 47 clients who failed to return p c f s more than 5 months 
after receiving them were contacted by telephone (7 men, 40 women). Of the 
47, 29 (61%) were referred for assessment of familial breast/ovarian cancer. The 
non-responders gave 57 reasons for not returning p c f s. Most reasons related to 
difficulties completing the family history form [n = 35 (61%)]. Other reasons 
included appointment not a priority because of ongoing cancer treatment (n = 4), 
concerns about genetic information (n = 4), not understanding why the referral 
was made (n = 2), recent death of a close relative (n = 2), and concerns about 
family confidentiality (n = 1).
Two thirds [n = 30 (63%)] indicated they wanted an appointment “now” and 
would return their p c f s (2 men, 28 women; 18 familial breast/ovarian). However, 
only 13 (43%) returned p c f s in the 6-month period after contact. almost all 
reported difficulties completing the family history form [n = 28 (93%)].
One third [n = 17 (36%)] indicated that they would not return p c f s; 11 did 
not want an appointment, and 6 did not want an appointment, but would consider 
re-referral at a later date (5 men, 12 women; 11 familial breast/ovarian). Of the 
17, 7 (41%) reported difficulties filling out the family history forms.
Conclusions: almost 2 in 3 non-responders want an appointment, but have 
not returned their p c f s, primarily because of difficulties with the family history 
form. We need to explore ways to assist completion of family history forms while 
minimizing the impact on genetic counsellor workload and showing respect for 
passive indications by non-responders that they do not want an appointment.
Pre-implantation Genetic Diagnosis for BRCA1/2:  
The Patients’ Perspective
L.R. Rubin,* A. Werner–Lin,† K. Hurley,‡ R. Stern,‡ A. Phillips,* 
M. Sagi,§ K. Offit.‡ *New School for Social Research, †New York 
University, ‡Memorial Sloan–Kettering Cancer Center, and §Hadassah 
University Hospital, New York, New York, U.S.A.
Objectives: BRCA1/2 carriers face a 50% chance that mutations will be 
transmitted to their offspring, and concern about passing on BRCA1/2 is a common 
reason for genetic testing. Pre-implantation genetic diagnosis (p g d ) is a promising 
technology for BRCA carriers. Pre-implantation genetic diagnosis is a type of 
assisted reproductive technology that involves genetic analysis of embryos obtained 
through in vitro fertilization. Couples can transfer only mutation-free embryos 
to the mother’s uterus to initiate pregnancy. However, use of p g d  for adult-onset 
cancer susceptibility is also controversial. as health care professionals increasingly 
become involved in discussions of family planning and reproductive technologies 
in their work with hereditary breast/ovarian cancer, the viewpoints of patients may 
provide insight for genetic counsellors and physicians attempting to navigate this 
ethically complex terrain. We report findings of a qualitative investigation of the 
views of reproductive-age BRCA1/2 mutation carriers regarding p g d , focusing on 
suggestions for integrating p g d  into medical practice.
Methods: Reproductive-age patients (n = 22; 21 women, 1 man; 91% 
European American), recruited from the clinical genetics service of a national 
comprehensive cancer centre, participated. Participants view a brief presentation 
regarding p g d  for BRCA1/2 mutations, followed by an in-depth interview about 
their attitudes toward using p g d  to prevent transmission of BRCA1/2 mutations, 
including their suggestions for discussing p g d  in the context of cancer-risk 
counselling. Interviews are recorded and transcribed verbatim, and analyzed 
using methods of grounded theory.
Results: Themes regarding information management—including timing, 
delivery, and depth—were discussed. although most participants want some 
information about p g d , suggesting it is “at least glossed over” in the initial 
counselling session, many emphasized that information should be limited, 
maintaining the focus on the patient undergoing testing/counselling.
Conclusions: BRCA1/2 mutation carriers are interested in learning 
about p g d ; physicians and genetic counsellors must be prepared to discuss this 
technology. Suggestions are provided for tailoring information to the needs and 
values of patients.
To	Test	or	Not	to	Test:	The	Influence	of	Ashkenazi	Jewish	Ethnicity
N. Schonberger. Sharsheret, Teaneck, New Jersey, U.S.A.
Cancer genetic counsellors are well aware of the increased risk for 
individuals of ashkenazi Jewish background carrying a BRCA mutation and of the 
fact that breast/ovarian cancer is more likely to have a genetic basis in Jewish than 
in non-Jewish families. What they may not be as familiar with, is the existence 
of a community of mainly religious Jewish women who are resistant to genetic 
counselling/testing because of unique issues surrounding their religious beliefs. 
Some Jewish women may find that breast/ovarian cancer treatments and/or genetic 
testing present religious dilemmas above and beyond the emotional dilemmas that 
all women confront with cancer. When faced with a diagnosis of breast or ovarian 
cancer, these women have questions and specific psychosocial concerns that may 
not be understood by the general cancer community, including genetic counsellors 
and cancer support groups. Some of their concerns surround issues of community, 
the Mikvah (ritual bath), and cancer as a stigma affecting marriage prospects. 
These questions need to be addressed by sources knowledgeable in Jewish lore 
and practices. A national, not-for-profit organization was formed several years 
ago to address these unique psychosocial, genetic, and practical issues pertinent 
to Jewish women living with or at high risk of breast cancer. acquaintance with 
this organization and an in-depth description of these issues will be the substance 
of this poster, so that professionals who meet with resistance on the part of their 
Jewish patients will have a better understanding of how to give them the support 
they need within the parameters of Jewish religious customs.
Ethical Aspects of Pre-implantation Genetic Diagnosis  
for BRCA1/2
S. SenGupta,* K. Fordham,* P. Serhal,† D. Ranieri,† T. Mamas,*  
S. Jaroudi,* S. Dhanjal,* G. Kakourou,* A. Doshi,† J. Harper,*  
J. Delhanty.* *University College London and †Centre for  
Reproductive and Genetic Health, London, U.K.
Objectives: Individuals with inherited breast and ovarian cancer face 
difficult ethical choices when making reproductive decisions. In pre-implantation 
genetic diagnosis (p g d ), embryos created by in vitro fertilization are genetically 
tested and unaffected ones are implanted. This study aimed to determine if 
couples attempting p g d  to exclude BRCA1/2 mutations faced ethical and clinical 
challenges different from those for other cancer predispositions.
Methods: Couples referred for p g d  for cancer predisposition had a 
preliminary consultation to outline the process. applications for treatment licenses 
were made to the Human Fertilization and Embryology Authority (h f e a ) for each 
new disorder and for individual patients with BRCA1/2 mutations. applications 
were also made for National Health Service funding.
Results: Between June 1, 1999, and May 31, 2009, 100 referrals were made 
for p g d  for 15 different cancer-predisposing genes. among 61 couples who opted 
for p g d , work-up was started for 41 couples who received funding. Overall, 18 
cycles of p g d  were completed for 12 couples, resulting in the birth of 5 healthy 
singletons and 4 ongoing pregnancies (pregnancy rate of 50% (9/18) per p g d  cycle 
started). The largest referral group was for breast and ovarian cancer attributable 
to BRCA1 (25 couples) and BRCA2 (6 couples). However, only 35% (11/31) from 
this group opted for p g d  as compared with 87% (13/15) for NF1, 71% (12/17) 
for RB1, and 65% (11/17) for APC mutations. Patients with BRCA1/2 mutations 
refused p g d , because the time taken by the sequential process of funding, protocol 
development, and h f e a  licensing interfered with their planned prophylactic 
surgery. Couples with children rarely chose to have p g d .
Conclusions: The uptake of p g d  for BRCA1/2 is clearly much less than for 
other cancer predispositions. Our study shows that this finding has as much to do 
with treatment of the female partner as the fact that BRCA1/2 have incomplete 
penetrance compared with other cancer predispositions.
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Phenotype of BRCA1/2 Large Genomic Rearrangements
K.M. Shannon, G. Chan–Smutko, D. Patel, M. Jacobs Gabree,  
P.D. Ryan. Massachusetts General Hospital Center for Cancer  
Risk Assessment, Boston, Massachusetts, U.S.A.
Objectives: Most large genomic rearrangements (l g r s) in BRCA1 and 
BRCA2 are missed using conventional sequencing technologies. In the United 
States, l g r s can be found using the BraCanalysis large rearrangement Test 
(b a r t ) offered by Myriad Genetics. The b a r t  is performed in parallel with d n a  
sequencing on individuals who meet clinical criteria set by Myriad Genetics. The 
b a r t  can be ordered separately for individuals who do not meet the established 
criteria. We were interested in determining how many of our patients that carried 
an l g r  in BRCA1 or BRCA2 met the criteria.
Methods: We performed a retrospective chart review of individuals seen 
at our center for BRCA1/2 testing after the introduction of this new technology. 
The family histories of individuals with an l g r  were assessed and determined to 
meet or not meet the clinical criteria set by Myriad for inclusion of b a r t .
Results: In 5 individuals, an l g r  was detected on b a r t . all l g r s were in the 
BRCA1 gene and included del exon 5, del exons 1–2, del exons 19–20, and exon 
14–20del26 kb (2 individuals). In 1 of the 5, cancer history clearly fulfilled the 
Myriad criteria. In 2 of the 5, cancer histories fulfilled the Myriad criteria only 
because the genetic counsellor obtained cancer histories on the individual’s great 
aunts, great uncles, and great grandparents. In 2 of the 5, the individual’s personal 
and family cancer histories did not meet the clinical criteria set by Myriad.
Conclusions: although l g r s are expected to account for a small 
minority of mutations in BRCA1/2, the phenotypes of these l g r s are not well 
understood. Families harbouring an l g r  do not necessarily meet Myriad’s 
stringent criteria. Testing using b a r t  should be considered in all families who 
are offered BRCA1/2 testing.
Risk Prediction Models of Breast and Ovarian Cancer:  
What Are the Social and Ethical Issues?
M. Tinker,*† D. Avard,*† B.M. Knoppers,*† J. Simard.‡ *McGill  
University and †Centre of Genomics and Policy, Montreal; and ‡ 
Université Laval, Quebec City, Quebec, Canada.
risk prediction for breast and ovarian cancer involves a number of factors, 
including those that are established (such as family history, current age, age 
at menarche) and those that are genetic (such as a positive BRCA1 or 2 gene 
mutation). The integration of breast cancer risk assessment models that take 
into consideration gene mutations raises a number of ethical, legal, and social 
concerns with regard to defining risk and risk categories and communicating risk 
information to the patient, and with regard to the potential value of the information 
for family members, the privacy and confidentiality of the information, and the 
potential misuse of the information by third parties. Thus, utilization of risk 
assessment models requires awareness of the ethical dilemmas. To gain a better 
understanding of the information available to the public, policymakers, and health 
professionals concerning risk assessment models for breast and ovarian cancer, 
we will review policies and position statements issued by international, regional, 
and national agencies and the relevant academic literature. We will highlight the 
differences and similarities between various policy statements with the purpose 
of elaborating the ethical considerations that could guide the development of 
risk assessment models.
Is Increased Susceptibility to Breast Cancer an Extracolonic  
Manifestation of MYH Polyposis? Report of a Canadian Kindred
E. Tomiak, E. Smith, K. Boycott. Children’s Hospital of Eastern  
Ontario, Ottawa, Ontario, Canada.
Objectives: Bi-allelic mutations of the MYH gene, implicated in base 
excision repair, are known to cause adenomatous colorectal polyps and are 
associated with very high colorectal cancer risk. The extracolonic manifestations 
of MYH-associated polyposis coli have not been fully characterized. One previous 
report suggested a substantially increased breast cancer (b c ) risk in female MYH 
mutation carriers (Nielsen et al. J Med Genet 2005;42:e54).
Methods: We describe an extended Canadian kindred in which a wide 
spectrum of tumour types occurred, including myeloma and colorectal, breast, 
bladder, and uterine cancers.
Results: Two previously recognized MYH mutations, G382X (1145G>A) 
and E182X (544G>T), were identified in the male proband who presented with 
colon polyps, colon cancer (age: 46 years), rectal cancer (age: 67 years), and 
myeloma (age: 47 years). In 3 of 5 female siblings b c s occurred. ages of onset 
were 37 years, 68 years, and 57 and 65 years in 1 sister who presented with 
bilateral b c  and in whom BRCA1/2 testing was inconclusive. Of the remaining 
2 sisters unaffected by b c , one died at age 47 with colon cancer. The MYH test 
results for the woman with bilateral b c and her sister who developed breast cancer 
at age 68, are pending and will be presented.
Conclusions: Our findings will contribute to the scant literature concerning 
b c risk in MYH mutation carriers. Further studies of the frequency of b c in mono-
allelic and bi-allelic mutation carriers are warranted.
Prevalence of BRCA1 and BRCA2 Germline Mutations Among 
Women with Carcinoma of the Fallopian Tube
D. Vicus,*† A. Finch,* I. Cass,‡ B. Rosen,† J. Murphy,† I. Fan,§  
L. Bradley,§ P. Sun,* R. Royer,* J. McLaughlin,§ B. Karlan,‡ S.A. 
Narod.* *Women’s College Research Institute and †Department of  
Gynecology Oncology, University Health Network, University of 
Toronto, Toronto, Ontario, Canada; ‡Cedars Sinai Medical Centre,  
Los Angeles, California, U.S.A.; and §Samuel Lunenfeld Research 
Institute, Toronto, Ontario, Canada.
Objectives: The purpose of this study is to determine the prevalence 
of BRCA1 and BRCA2 mutations among women with carcinoma of the 
fallopian tube.
Methods: Two series of women diagnosed with carcinoma of the 
fallopian tube were studied. The first series of subjects was identified from 
the Ontario Cancer registry. Those women were diagnosed between 1990 
and 1998 or between 2002 and 2004. The second series was identified from 
Cedars Sinai Medical Centre, los angeles, California, U.S.a. They were 
diagnosed between 1991 and 2007. Each subject was approached to provide 
a family history and a blood sample for genetic testing for mutations in the 
BRCA1 and BRCA2 genes.
Results: We recruited 116 patients with fallopian tube cancer (70 from 
Ontario, 46 from Los Angeles). A deleterious mutation was found in 36 patients 
(31.0%), 26 in BRCA1 (22.4%) and 10 in BRCA2 (8.6%). A family history of 
ovarian or breast cancer was positive for 26 women; of these, 15 had a mutation 
(57.5%). In 19 of the patients with a previous history of breast cancer, 15 (79.0%) 
had a mutation. Of the women who were diagnosed with fallopian tube cancer 
before the age of 60 years, 40.0% had a mutation, as compared with 19.2% of 
the women diagnosed after the age of 60 years.
Conclusions: approximately 31% of women with fallopian tube cancer 
have a mutation in BRCA1 or BRCA2. all patients diagnosed with invasive 
fallopian tube cancer should be considered candidates for genetic testing.
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Evaluation of a Cancer Risk Educational Interventional Tool for 
Underserved Women
R. Lee,*† M. Metrikin,* M. Beattie,*† G. Joseph,* D. Braithwaite,* 
K. Lamvik,*† S. Jafarieh,† B. Crawford,* J. Luce.*† *University of 
California and †San Francisco General Hospital, San Francisco, 
California, U.S.A.
Objectives: The purpose of this study is to evaluate the use of an educational 
tool for cancer risk education in underserved women. The tool is an audiovisual 
PowerPoint presentation used as an adjunct to genetic counselling.
Methods: The Cancer Risk Educational Interventional Tool (c r e dit) is 
a 15-minute story presentation (available in English and Spanish) showing 
a high-risk family of mixed race. It uses non-scientific images and language 
specifically designed for a lower-literacy multi-ethnic population. Participant 
questionnaires evaluating patient satisfaction, risk perception, knowledge of 
cancer genetics, and anxiety were administered before and after the intervention 
and at 1 year of follow-up.
Results: We recruited 52 women of diverse backgrounds (mean age: 47 
years; range: 27–69 years; 58% non-white; 59% college not completed; 11% 
viewing the presentation in Spanish). Of these participants, 15 reported a previous 
history of cancer, and 5 went on to receive genetic testing. We found an increase 
in knowledge following c r edit, specifically in regard to BRCA inheritance, 
BRCA-associated cancer risk, and risk-reducing options (all p < 0.05). Reports 
by 98% of the participants indicated that c r e dit helped them to learn more about 
cancer risk. Overall, patient anxiety decreased post-c r e dit (p = 0.02). Among 
36 participants who have been interviewed for long-term follow-up, we found 
that long-term knowledge overall did not change from post-c r e dit levels (p < 
0.05). There were no changes in anxiety or cancer worry compared with baseline 
(both p < 0.05).
Conclusions: The c r edit successfully increased knowledge regarding 
breast cancer genetics in this patient population without increasing anxiety or 
cancer worry in the long term. Our long-term goal is to perform a large-scale 
evaluation of c r e dit among underserved women at risk of hereditary cancer in 
public hospitals nationwide. additionally, we are developing versions aimed at 
african american and asian american patients.
Challenges of Applying Genetic Counselling and Testing in a 
Middle-Income Asian Country
S.H. Teo,*† E. Thirthagiri,* P. Kang,* D. Lee,* S.Y. Yoon,*  
N.A.M. Taib,† M.K. Thong,† C.H. Yip.† *Cancer Research Initiatives 
Foundation, Sime Darby Medical Centre, Subang Jaya, Selangor, 
and †University Malaya Medical Centre, Kuala Lumpur, Malaysia.
Objectives: The cost of genetic testing and the limited knowledge about 
BRCA1, BRCA2, and other genes in various ethnic groups has limited testing 
availability in medium- and low-resource countries, including Malaysia. 
Malaysia is a multi-ethnic asian country, composed of approximately 54% 
Malays, 25% Chinese, 7% Indians, and 14% others. In January 2003, the 
Malaysian Breast Cancer Genetic Study (MyBrCa) was established to
•  determine the prevalence of mutations in breast cancer genes;
•  develop statistical methods for the identification of those at risk;
•    examine the social, religious, and cultural issues of genetic counselling 
and testing in this asian setting.
Methods: Between January 2003 and december 2008, 901 breast 
cancer patients participated in MyBrCa. Of these, 305 medium- and high-
risk individuals have been analysed for mutations in BRCA1 and BRCA2 by 
sequencing and multiplex ligation-dependent probe amplification analysis. The 
applicability of the Manchester scoring system and b o a d i c e a  has also been tested. 
all patients with deleterious mutations in BRCA1 or BRCA2 were provided by 
genetic counselling by a genetic counsellor and clinical geneticist.
Results: In 43 unrelated individuals, deleterious BRCA mutations were 
found (22 BRCA1, 21 BRCA2), only 2 of which were recurrent. In addition, 61 
variants of uncertain clinical significance were identified (19 BRCA1, 42 BRCA2). 
We found that the predictive power of the b o a d i c e a  risk prediction model and 
the Manchester scoring system was better for BRCA1 than BRCA2, but both 
methods underpredicted the number of carriers in our cohort. We report numerous 
challenges in providing genetic counselling, including having multilingual 
counselling sessions, inaccurate family histories, and complex family dynamics 
(18 of 33 counselled probands were from polygamous/polyandrous families; 18 
had 6 to 10 and 10 had more than 10 first-degree relatives).
Conclusions: Taken together, studies in this typical asian multi-ethnic 
population underscore the need for collaborative studies among non-Caucasian 
populations to validate the role of genetic testing and the use of risk-prediction 
models in ensuring that the other populations in the world may also benefit 
from the genomics and genetics era.
A Randomized Controlled Trial of Population Testing for BRCA1/2 
Founder Mutations in the Ashkenazi Jewish Population
R. Manchanda,* U. Menon,* K. Loggenberg,* S. Gessler,* S. Sanderson,† 
I. Udeh,* N. Balogun,* J. Wardle,‡ I. Tomlinson,§ A. McGuire,|| U. Beller,# I. 
Jacobs.* *Department of Gynaecological Oncology, EGA Institute for Women’s 
Health, University College London, London, U.K.; †Mount Sinai University, 
New York, New York, U.S.A.; ‡Behavioural Sciences Unit, Department of 
Epidemiology and Public Health, University College London, §London Research 
Institute, Cancer Research UK, and ||Department of Health Economics, London 
School of Economics, London, U.K.; and #Department of Gynaecology, Shaare 
Zedek Medical Centre, Jerusalem, Israel.
Objectives: To compare a systematic population-based approach to genetic testing 
for cancer-predisposing genes with the current family history–based approach.
Methods: a randomized controlled trial for BRCA1/2 genes (disease model) in 
the Ashkenazi Jewish (a j ) community (population model), with two arms: population 
screening (study arm) and family history (control arm). Primary outcomes include 
BRCA founder mutations (f ms) detected; acceptability; psychological impact; uptake 
of screening or preventive strategies; and health economics. Inclusion criteria are age 
over 18 years and a j  ethnicity. Exclusion criteria are first-degree relationship to BRCA 
carriers and past BRCA testing.
recruitment depends on self-referral, and a variety of population-based 
strategies are used to increase awareness. all participants undergo genetic counselling 
(group or individual) before making a decision regarding testing. Consenting volunteers 
provide a blood sample and are subsequently followed at 7 days, 3 months, 1 year, 
2 years, and 3 years after the test result to ascertain the benefits and disadvantages 
of testing. Follow-up questionnaires evaluate attitude, knowledge, satisfaction, 
psychological impact, quality-of-life, uptake of screening or preventive strategies, 
lifestyle behaviours, and health economics.
Results: We present data on our experience of initial participants from the 
pilot phase of 1000 volunteers. Of the 450 people recruited to date, 31% are men, 
and 69% are women (median age: 59 years; interquartile range: 45 to 66 years). The 
post-counselling participation rate exceeds 85%. The founder mutation rate is 2.2% 
(95% confidence interval: 0.55% to 5.04%). Of these participants, 350 have been 
randomized, and 3 carriers were detected in the systematic screening arm, and 1 was 
detected in the family history arm.
Conclusions: Initial experience suggests that it is feasible to undertake a 
randomized controlled trial for population-based BRCA gene testing. Preliminary results 
show the presence of carriers in individuals without a strong family history of cancer.
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Genetic Counselling: What Is Important to Spouses of  
BRCA1-/2-Positive Women?
M. Cohen,* P. Kredow,† S. Friedman.‡ *Vanderbilt University School 
of Medicine, Nashville, Tennessee; †Center for Psychological Services, 
Northfield, Illinois; and ‡FORCE, Tampa, Florida, U.S.A.
Introduction: a limited number of studies have examined the interests 
and preferences of non-affected spouses in the process of genetic testing and 
counselling for genetic disorders that have sex-limited expression. Our hypothesis 
was that non-affected spouses of BRCA1- or BRCA2-positive women would 
have specific preferences and needs that were unaddressed. This pilot study 
ascertained those items.
Subjects and Methods: a questionnaire was distributed to attendees of 
the Men’s Facilitated Networking Session, f o r c e  (Facing Our Risk of Cancer 
Empowered) meeting. All participants, but 1 male, were Caucasian (11/12); 
ages ranged from 27 years to 75 years (median age: 48 years). The sample was 
not socioeconomically representative of the general population: 92% were in 
professional occupations or retired; 100% had a bachelor’s degree; 42% had 
advanced graduate degrees.
Results: In the study group, 100% prioritized genetic counselling before 
testing and did not differentiate between determining a son’s or daughter’s 
risk; 92% desired discussion of insurance discrimination issues; 83% preferred 
receiving results with family members present; 75% felt that determining the 
cancer risk for self and offspring was very important, wanted a summary letter 
to share with relatives, and wanted information about local and national support 
groups, available research protocols, and referrals to other specialists; 50% both 
desired an additional, separate counselling session for the spouse and offspring 
without the proband present, and felt that the sex of the health care provider was 
not important; 25% desired an annual visit with a genetic counsellor.
Conclusions: Non-affected spouses have unmet preferences and needs. 
Important needs were insurance discrimination issues, receiving results in person, 
risks for self and offspring, and a summary letter and referrals to support groups and 
research programs. The sex of the health care provider and of a child’s future cancer 
risk were least important. additional counselling sessions without the spouse present 
are desired. Genetic counsellors should be prepared to address these preference and 
needs. additional research is needed to develop tools for this purpose.
The Lived Experiences of Women Possessing a Genetic 
Predisposition to Developing Breast Cancer:  
A Grounded Theory Study
J. DiMillo,* A. Samson,* S. Lowry,† L. Corsini,† A. Bodurtha,† S. 
Verma,†§ E. Tomiak.‡† *Faculty of Education, University of Ottawa, 
†Women’s Breast Health Centre, The Ottawa Hospital, ‡Department 
of Genetics, Children’s Hospital of Eastern Ontario, and §The Ottawa 
Regional Cancer Centre, The Ottawa Hospital, Ottawa, Ontario, Canada.
Objectives: Genetic testing to determine whether a woman carries a BRCA1 
or BRCA2 mutation, which may entail an up to 80% lifetime risk of developing 
breast cancer, is relatively recent. There is an apparent void in the literature 
investigating the lived experiences of these women, and qualitative studies of 
this nature are virtually nonexistent. The purpose of this ongoing study is to better 
comprehend the lived experiences of young women who have been identified 
as carrying a BRCA1/2 mutation. In our study, concepts such as the nature of 
these women’s received support, the impact of the experience, and the presence 
of stigmatization, are being examined.
Methods: Six women between the ages of 20 and 40 years who were 
identified as BRCA1/2 mutation carriers will be invited to participate in a 
semi-structured interview. The interview will be digitally recorded, transcribed, 
and analyzed through the use of constant comparison analysis (Glaser and 
Strauss, 1967).
Results: This preliminary report is based on the first completed interview. 
Three major dimensions emerged from 16 raw data themes. More specifically, 
the themes of Confirmation of Fears, Concern, and Coping were revealed. 
Generally, this woman was found to experience various negative emotions. The 
discovery of a positive test result was perceived to be a confirmation of previous 
fears, which then led to fears for her daughters and about judgments from others. 
Finally, the woman was able to engage in coping behaviours such as altering 
her way of life and seeking social support. results for the remaining 5 planned 
participants will be presented.
Conclusions: The results of this qualitative study may lead to 
recommendations regarding the additional support and psychological assistance 
that should be considered in young women undergoing genetic testing for 
inherited predisposition to breast cancer.
Impact of a hospital-Based Focused, Counsellor-Led Support 
Group Among BRCA Carriers
W. Ducaine, L. Dohany, D. Zakalik. Beaumont Hospital, Royal Oak, 
Michigan, U.S.A.
Objectives: Individuals carrying a mutation in the breast and ovarian cancer 
susceptibility genes BRCA1 and BRCA2 often face significant psychological and 
emotional challenges. To address the unique medical and psychological needs 
of BRCA carriers, we implemented a hospital-based, focused support group for 
BRCA mutation carriers led by genetic counsellors. This study evaluates the 
impact of such a support group on the knowledge, emotional well-being, and 
family dynamics of BRCA mutation carriers.
Methods: We invited 115 individuals carrying a BRCA mutation to 
participate in a voluntary electronic questionnaire about their experience in the 
support group. Participants were asked to rate the impact of the support group on 
medical knowledge, emotional needs, family dynamics, and overall benefit.
Results: The online questionnaire was completed by 42 individuals, 
62% of whom were BRCA1-positive, 30% were BRCA2-positive, and 8% were 
BRCA-negative family members. Most of the responders were between the ages 
of 40 and 55 years. Of the respondents, 85% felt that attending the support group 
significantly improved their medical knowledge; 70% felt that the group provided 
significant emotional support; and 96% felt that they were better able to broach 
the subject of their BRCA status with family members. Slightly more than half 
of respondents (56%) experienced significantly lowered anxiety levels regarding 
their BRCA status, and a preponderance (78%) reported diminished feelings of 
isolation since attending the support group.
Conclusions: Involvement in a focused, interactive BRCA-positive 
support group resulted in significant improvement in medical knowledge, family 
dynamics, and anxiety in the participants. Genetic counsellors with a specialty 
in cancer genetics proved to be effective in leading the sessions and achieving 
its goals. This study demonstrates that ongoing involvement in similar support 
groups provides BRCA carriers with important benefits in dealing with the many 
challenges faced by this unique group of individuals.
Decision-Making About Inherited Breast/Ovarian Cancer Risk: 
Exploring Dimensions of Genetic Responsibilityf
H. Etchegary,* F. Miller,† S. deLaat,‡ B. Wilson,§ J. Carroll,|| M. 
Cappelli.# *Eastern Health, Memorial University, St. Johns’s, 
Newfoundland and Labrador; and †University of Toronto, Toronto, 
‡McMaster University, Hamilton, §University of Ottawa, Ottawa, 
||Mount Sinai Hospital, Toronto, and #Children’s Hospital of Eastern 
Ontario, Ottawa, Ontario, Canada.
Background and Objectives: Because genetic information has implications 
for family members, some choices about genetic risk may be influenced by 
perceptions of responsibility to relatives. drawing upon 25 semi-structured 
interviews with test recipients in Canada, this study explored decisions about 
inherited breast/ovarian cancer.
Methods: Semi-structured interviews.
Results: Qualitative data analysis revealed the pervasive significance of 
genetic responsibility in test decisions. We highlight three dimensions of genetic 
responsibility:
•  To know about the self for self
•  To know about the self for others
•  To know about the self to oblige others to know
Conclusions: These dimensions of genetic responsibility have implications 
for test decisions, family relationships, and other family members’ desire to know 
(or not know) and to act (or not act) with respect to their own genetic risk. In 
particular, genetic responsibility may play out as a framing of a relative’s moral 
obligation to know their risk that could obviate any interest they might have in not 
knowing. We conclude that perceptions of responsibility to, and of, other family 
members be thoroughly explored in genetic counselling sessions.
f  Published in J Genet Couns 2009;18:252–64.
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THIrd INTErNaTIONal SYMPOSIUM ON HBOC
Women’s Constructions of the “Right Time” to Consider Decisions 
About Prophylactic Surgery
A.F. Howard,* J.L. Bottorff,† L.G. Balneaves.* *University of British 
Columbia, Vancouver, and †University of British Columbia, Kelowna, 
British Columbia, Canada.
Women who are notified that they carry a BRCA1/2 mutation are presented 
with surgical options to reduce their risk of breast and ovarian cancer, including 
risk-reducing mastectomy (r r m ) and risk-reducing oophorectomy (r r o ). There 
is growing evidence that a subgroup of women do not make decisions about 
r r m  and r r o  immediately following genetic testing; rather, they consider these 
decisions years later. Women’s perspectives on the timing of these decisions 
are not well understood. accordingly, the purpose of this study was to describe 
how women construct the “right time” to consider decisions about r r m  and r r o . 
In-depth interviews were conducted with 21 women who were BRCA1/2 carriers 
and were analyzed using qualitative, constant comparative methods. The study 
findings revealed how important it was for the women to make decisions about 
r r m  and r r o  one at a time. Moreover, the women constructed the “right time” to 
consider decisions about risk-reducing surgery to be when
•  decisions fit into their lives,
•  they had enough time to think about decisions,
•  they were ready emotionally to deal with decisions,
•  all of the issues and conflicts were sorted out,
•  there were better options available, and
•  the health care system was ready for them.
These findings offer novel insights relevant to health care professionals who 
provide decision support to women considering r r m  and r r o  decisions.
Using Participatory Action Research Techniques, healthy BRCA 
Mutation Carriers Design a Model of Care
P. Mor. Shaare Zedek Medical Center, Jerusalem, Israel.
Objectives: To fill a gap in health care and health promotion for healthy 
women testing positive for BRCA gene mutations.
Methods: Using participatory action research techniques involving a series 
of focus group interviews and intensive discussions, we worked closely with 23 
women recruited from a genetics clinic. The goal was to define unmet care needs 
for healthy women with BRCA gene mutations.
Results: Through their narratives, carriers described dilemmas that affect 
and sometimes radically change life perspectives. They identified ongoing stress as 
a result of the constant threat of illness, knowledge that the mutation can be passed 
on to children, the need for heightened surveillance, and the difficulty of making 
decisions regarding prophylactic surgeries and other risk-reducing measures. 
Inconsistent and inaccurate information from health care providers, barriers to 
reimbursement for approved screening studies and prophylactic procedures, and a 
lack of psychosocial support were named as major health care issues. Participants 
suggested a “one-stop” centre to provide expert care and smooth bureaucratic 
barriers to screening and preventive procedures. Their ideas were presented to 
focus groups of health care professionals who manage care for healthy carriers, 
with the result that a multispecialty outpatient clinic for healthy carriers was 
opened. The clinic provides improved access to imaging surveillance; expert 
medical consultation; counselling by a nursing coordinator, psychologist, and 
sexologist; and medical information. Study findings strengthened interdisciplinary 
connections among participating nurses, genetic counsellors, and physicians, and 
supported a holistic health promotion model.
Conclusions: The primary study outcome was inception of a one-stop 
multidisciplinary clinic incorporated into an existing health care setting. The 
clinic provides medical and psychosocial services, including improved access to 
imaging surveillance, and expert medical consultation and counselling.
Testing Young People for BRCA1/2: Challenges from health 
Professionals’ Perspective
A. Navarro de Souza,*† N. Wong.† *McGill University and †Jewish 
General Hospital, Montreal, Quebec, Canada.
Objectives: To examine the challenges facing health care providers in 
deciding to test adult children (individuals 17 years of age and older) for a 
mutation in BRCA1/2.
Methods: a focus group was conducted consisting of 1 medical geneticist 
and 3 genetic counsellors, who all specialize in cancer genetics and who all have 
encountered a case in which a young individual requested testing for a mutation 
in BRCA1/2 known to run in the family. The session was audiotaped. Themes 
were extracted and examined.
Results: recognizing the different arguments in favour of and against 
testing young people based on theoretical benefits and harms, the group discussed 
their clinical experience and their case-based decisions. The adult children 
were mainly female and came with only 1 parent who was not necessarily the 
carrier. The prominent theme encountered was to elicit the extent to which the 
young person’s demand for the test was “voluntary,” that is, being “influenced” 
but not “coercively” by the parents. This assessment became more difficult 
by the value of autonomy based on a rational individual, traditional bias on 
psychological assessment, and the limitations of professional training for the 
changing demands in this select population. Sex differences in the parent’s 
perspectives on the daughter’s desire to seek testing and contradictory behaviour 
in relation to being tested or to receiving the result were also relevant themes 
for the group. an illustrative case in which the resource of a second opinion was 
used is also presented.
Conclusions: In the face of the “new generation” seeking predictive testing 
for BRCA1/2, this study illustrates the need for more research and training for 
the professionals who are more often involved with a complex family dynamic 
rather than an individual choice. Case-by-case decision based on second opinion 
or psychological assessment in more difficult family interactions can be adequate 
resources in some cases.
Breast Cancer Risk Decision: The Experience of Unaffected 
Carrier Women of Different Cultural Backgrounds
A. Navarro de Souza,*† N. Wong,† S. Zaor,† D. Groleau.*† *McGill 
University, and †Jewish General Hospital, Montreal, Quebec, Canada.
Objectives: This study investigated the experience of unaffected women 
carrying a mutation in BRCA1 and BRCA2 and their different choices in strategies 
to manage breast cancer risk. We are interested in identifying the meaning 
that women attribute to their test result and to the various risk management 
strategies, and whether the meaning and experience vary according to culture. 
To the best of our knowledge, there are no qualitative studies on psychocultural 
determinants for BRCA-mutation carrier women on the uptake of effective 
cancer prevention options. This aspect is important to investigate because of 
the observed international and national differences in uptake for the various 
risk-reducing strategies.
Methods: a cross-sectional qualitative study is being done. a purposive 
sample consisting of eligible women is being recruited from a large university-
affiliated hospital in Montreal, Quebec. To be eligible for this study, women 
must be of French-Canadian or ashkenazi Jewish descent, unaffected at the 
time of genetic testing, with knowledge of their BRCA1/2 mutation status for 
at least 3 years, and a decision in favour of, or against, bilateral prophylactic 
mastectomy made before a diagnosis of breast cancer, if applicable. a theoretically 
driven, semi-structured qualitative interview protocol designed to elicit illness 
narratives in health research—the McGill Illness Narrative Interview—is being 
used. audiotapes will be transcribed verbatim. We chose the narrative approach 
to perform a data analysis that allows us to capture individual and collective 
meanings and the complexities of the experience, which will be contextualized 
in the cultural backgrounds of the patients.
Results: Currently, the interviews and analysis are in process, and the 
results are expected to provide new knowledge on the psychocultural determinants 
of women’s experience of undergoing BRCA genetic testing and women’s 
decisions on risk-reduction strategies.
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MEETING aBSTraCTS
Factors Associated with Choosing Risk-Reducing Mastectomy in 
BRCA Mutation Carriers
K. Singh, X. Li, O. Gordon. Cedars Sinai Medical Center, Los Angeles, 
California, U.S.A.
Objectives: lifetime risk of breast cancer among BRCA mutation carriers 
is markedly reduced with prophylactic mastectomy (p m), yet only a subset elect 
to undergo the procedure. This study investigates factors that might influence 
patients’ decisions regarding risk-reducing surgery.
Methods: We conducted a prospective observational study of BRCA 
mutation carriers with no personal history of cancer presenting to Cedars 
Sinai Medical Center between 1999 and 2009. Charts were analyzed for 
factors that might have influenced choices regarding prophylactic surgery, 
including age, family history, history of breast biopsy, and history of previous 
cosmetic surgery.
Results: Of 59 BRCA carriers, 22 (37.3%) elected p m. average time from 
results disclosure to p m was 1.4 years. In the p m group, as compared with the 
no-p m group, history of mother dying of breast cancer was 63.6% versus 5.4%, 
p < 0.001, and history of a mother dying of ovarian cancer was 13.6% versus 
43.2%, p = 0.02. Of those who had p m, 96% as compared with 40.5% in the no-
p m group had bilateral salpingo-oophorectomy (b s o ), p < 0.001. Interestingly, 14 
of 15 patients (93.3%) who had b s o  in the no-p m group had a history of mother 
dying of ovarian cancer. No significant differences in mean age at the time of 
genetic testing, number of affected first-degree relatives, history of breast biopsy, 
or history of cosmetic surgery were detected between the groups.
Conclusions: BRCA carriers with family history of a mother dying of 
breast cancer were most likely to choose p m. among those who did not undergo 
p m, uptake of b s o was highest among those whose mother died of ovarian cancer. 
The impact of having a mother die of cancer may be of under-recognized import 
in patient attitudes regarding prophylactic procedures. additional studies are 
needed to support these findings and to assess whether directly addressing this 
life experience during genetic counselling influences patient behaviour regarding 
screening versus prophylactic surgery.
high Satisfaction Rates in Women after Deep Inferior Epigastric 
Artery Perforator Flap Breast Reconstruction
J.P. Gopie,* T.H.C. Damen,† R. Timman,† E.H. Kunst,* P.J.C. Bresser,† 
C. Seynaeve,† M.B. Menke–Pluijmers,† M.A.M. Mureau,† S.O.P. Hofer,‡ 
A. Tibben.*† *Leiden University Medical Center, Leiden, and †Erasmus 
University Medical Center, Rotterdam, Netherlands; and ‡University of 
Toronto, Toronto, Ontario, Canada.
Objectives: Breast reconstruction (b r) is aimed at improving quality of life 
(q o l ) after mastectomy. Patient satisfaction is an important indicator in evaluating 
the success of b r . This study explored patient satisfaction and its determinants in 
women undergoing deep inferior epigastric artery perforator (d i e p ) flap b r  and 
the impact of the procedure on body image, sexuality, and q o l .
Methods: Patient satisfaction and q o l  was studied in 72 women who 
underwent d i e p  flap b r , using a study-specific questionnaire and the Short 
Form 36.
Results: Patient satisfaction was very high. approximately 90% of 
patients reported that they had been sufficiently informed about the procedure 
and its consequences, that their preoperative expectations had been met, that 
the reconstructed breast felt like their own, that they would choose the same 
procedure again, and that they would recommend this procedure to a friend. 
Patient satisfaction was positively and significantly related to the reconstructed 
breast or breasts feeling like their own. Women with secondary reconstructions 
were more positive about changes in sexuality and femininity than were women 
with primary b r s. There were no clinically relevant differences in q o l  between 
our study population and a random sample of dutch females.
Conclusions: Women with d i e p  flap b r s reported high satisfaction rates. 
However, to compare these satisfaction rates with other forms of b r, a prospective 
study in comparable groups is currently ongoing.
Opening the Psychological Black Box in Genetic Counselling: 
Recollections and Interpretations of Counselees
J. Vos,* J. Oosterwijk,† E. Gomez–Garcia,‡ F. Menko,§ C.J. van 
Asperen,* A.M. Jansen,* A. Stiggelbout,* A. Tibben.*|| *Leiden 
University Medical Center, Leiden; †University Hospital Groningen, 
Groningen; ‡Maastricht University Medical Center, Maastricht; §Free 
University Medical Center, Amsterdam; and ||Erasmus Medical Centre, 
Rotterdam, Netherlands.
Objectives: It is often assumed that the communication of d n a  test results 
has direct psychological and medical consequences for the counselee. However, 
subjective factors may mediate between d n a  test result and impact. The present 
study assessed mediation effects of the counselee recollections and interpretations 
regarding cancer risks and the likelihood that the cancer in their family is heritable.
Methods: In this retrospective study, women tested for BRCA1 or BRCA2 
completed questionnaires 5 years after disclosure. Participants had received an 
unclassified-variant test result (n = 76), uninformative-negative d n a  test results 
(n = 76), or pathogenic mutations (n = 51) in BRCA1/2.
Results: Of the counselees, 10%–42% correctly recalled and interpreted 
what the counsellors actually communicated about cancer risks and heredity 
likelihood. Cancer risks were recalled and interpreted as lower, heredity 
likelihood as higher. Moderate correlations between recalling and interpreting 
suggested distinctive processes. Cancer risks were recalled more correctly when 
measured in percentages instead of in categories. Unclassified d n a  variants were 
recalled and interpreted as giving very high cancer risks and heredity likelihood, 
uninformative results as very low. Psychological and medical outcomes were 
predicted by cancer risks and heredity likelihood as actually communicated by 
counsellors. However, these predictions were lowered or became insignificant 
when the recollections and interpretations of the counselees were included in 
analyses and path analyses, suggesting mediation. Overestimations predicted 
life changes, breast/ovarian removal in all counselees, and low quality of life 
in unclassified variants.
Conclusions: The impact of test results is strongly mediated by the 
recollections and interpretations of communicated risks by counselees. Subjective 
processes should be addressed during counselling, especially if unclassified-
variants are disclosed.
P120
P118 P119
PSYCHO-ONCOLOGY